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ABSTRACT OF DISERTATION

THE ROLE of SYNTAXIN AND TOMOSYN
IN PLATELET SECRETION

Platelet secretion is important for hemostasis and thrombosis. The components
released are also involved in atherosclerosis, inflammation, angiogenesis, and tumor
growth. Though the exact mechanism(s) of platelet secretion is still elusive,
accumulating evidence demonstrates that SNAREs (Soluble N-ethylmaleimide Sensitive
Factor Associated Receptor) and their regulatory partners are critical for platelet
exocytosis. Formation of a trans-bilayer complex composed of one v-SNARE (i.e.
VAMPs) and two t-SNAREs (i.e. syntaxin and SNAP-25-type) is minimally required for
membrane fusion. Regulatory proteins control the rate and specificity of the complex
assembly. VAMP-8 and SNAP-23 (a SNAP-25-type t-SNARE) are clearly important;
however, the identity of the functional syntaxin has been controversial. Previous studies,
using anti-syntaxin antibodies in permeabilized platelets, suggested roles for both
syntaxin-2 and -4. These conclusions were experimentally tested using platelets from
syntaxin knockout mice and from a Familial Hemophagocytic Lymphohistiocytosis type
4 (FHL4) patient that lacks syntaxin-11. Platelets from syntaxin-2 and syntaxin-4 single
or double knockout mice had no significant secretion defect. However, platelets from the
FHL4 patient had a robust defect, though their morphology, activation, and cargo levels
appeared normal. Semi-quantitative western blotting showed that syntaxin-11 is the most
abundant syntaxin in both human and murine platelets. Co-immunoprecipitation
experiments showed that syntaxin-11 forms SNARE complexes with VAMP-8 and
SNAP-23. These data conclusively demonstrate that syntaxin-11, but not syntaxin-2, or 4, is required for platelet exocytosis.
We also show that a syntaxin binding protein, tomosyn-1, is important for platelet
exocytosis and hemostasis. Tomosyn-1 was identified from platelet extracts using
affinity chromatography, RT-PCR analysis, and western blotting analysis. Tomosyn-1
was co-immunoprecipitated with syntaxin-11/SNAP-23 from both resting and activated

platelet extracts. Platelets from tomosyn-1-/- mice displayed a secretion defect, but their
morphology and activation appeared normal. Tomosyn-1-/- mice showed impaired
thrombus formation in two different injury models. Given the importance of platelet
secretion to hemostasis, it is hoped that the insights gained from these studies in this
dissertation will help to identify new and more valuable therapeutic targets to control clot
formation.
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Chapter One
Introduction

Platelet Overview:
Platelets are small, anucleated blood cells produced from megakaryocytes in bone
marrow [1]. Their structures are simple: they contain plasma membrane, microtubules,
mitochondria and three types of storage granules: dense granules, α-granules and
lysosomes. Platelets respond to vascular damage via surface receptors that directly bind
to agonists exposed or produced at the site of damage. The resulting activation leads to
increases in intracellular Ca2+, dramatic changes in cell shape and release of granule
contents. These steps help to attract more platelets which aggregate to form a thrombus,
which stops bleeding. Hypoactive platelets lead to bleeding problems [2]; hyperactive
platelets cause spurious thrombosis which leads to occlusive events such as heart attack
or stroke [3, 4].

Thus, regulating and controlling platelet function has significant

therapeutic value for preventing cardiovascular diseases.
Secretion of the cargo from the platelet’s three stores is critical for hemostasis [1,
5-7] and important for other diseases [8-10]. Hemostasis is a physiological process to
stop bleeding from an injured vessel. Platelets first adhere and aggregate to the damaged
site to form a platelet rich thrombus.

ADP release from dense granules serves as

secondary agonists to activate and recruit other circulating platelets, thus it is important
for secretion dependant platelet aggregation.

Followed by the coagulating cascade

activation and thrombin generation, a fibrin rich clot is formed to temporarily seal the
vessel wall.

Fibrinogen and Factor V from α-granules participate in fibrous clot

formation, clot retraction, and coagulation [1, 11, 12]. Finally, the released growth
factors from α-granules initiate the wound repair. Lysosomal proteins are thought to
assist in clot remodeling. Platelet secretion defects have been shown to ablate or at least
delay thrombogenesis in murine models [13]. Platelet secretion is not only important for
hemostasis and thrombosis but it is also associated with many pathological processes
such as inflammation, atherosclerosis, angiogenesis and tumor growth. Platelets are
thought to contribute to the initiation and propagation of the inflammatory process
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through secretion of bioactive components such as chemokines, cytokines, and
procoagulants from α-granules [7, 14]. Platelets with dense granule secretion defects
show

reduced

formation

of

platelet-leukocyte

aggregates

and

arterial

[15].

Atherosclerosis is a chronic inflammatory disease on the arterial walls characterized by
the infiltration of immune cells [8, 9]. Accumulating evidence demonstrates that platelets
play a role in both the initiation and progression of atherosclerosis [16, 17]. Chemokines
and P-selectin from α-granules are thought to be the factors. Specific knockout of platelet
P-selectin reduces plaque lesion development in apoE null mice [18]. Inhibition of the
interaction between platelet chemokines decreases the progression of atherosclerosis [1921]. Upon stimulation, platelets release a variety of pro-angiogenic proteins, such as
vascular endothelium growth factor (VEGF), platelet-derived growth factor (PDGF),
fibroblast growth factor (FGF), and epidermal growth factor (EGF) [5].

These

angiogenic activators promote vessel wall permeability and proliferation of endothelial
cells and fibroblasts, thus facilitating tumor growth [10, 22].

Understanding the

mechanism of platelet secretion and secretory machinery has the potential to lead to the
development of new drug targets for bleeding problems, thrombosis, atherosclerosis,
heart attack, stroke, cancer, and inflammation.

Platelet Structure and Function
Platelets contain mitochondria, microtubules, granules, plasma membrane and a
specialized region of the plasma membrane called the open canalicular system (OCS).
On the plasma membrane, there are receptors including protease activated receptors
(PAR1, 3, 4), GPVI, and purinergic receptors (P2Y1 and P2Y12) which are involved in
platelet activation [1, 23]. The OCS is an invagination of the plasma membrane which is
thought to be an important site for granule secretion and endocytosis [24]. There are
three types of granules (Figure 1): α-granules, dense granules, and lysosomes. The most
abundant granules, α-granules, contain polypeptides such as platelet derived growth
factor (PDGF), cytokines, von Willebrand factor, P-selectin, fibrinogen, GPIIb/IIIa and
platelet factor IV (PF4). The cargo released from α-granules are important for platelet
aggregation, wound repair, and inflammation. Dense granules contain small molecules
such as ADP, calcium, magnesium, and 5-hydroxytryptamine (5-HT, serotonin), which
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serve as signaling molecules or ligands to recruit and activate other platelets to the lesion
site. Lysosomes contain hydrolytic enzymes such as β-hexosaminidase, cathepsin D, and
acid phosphatases, which are thought to be important for clot remodeling. Platelets also
contain cytoskeletal structures which are necessary for maintaining the resting platelet
and changing its shape during activation.
The primary function of platelets is the maintenance of pressurized vasculature
integrity. When the receptors on the platelet surface detect vascular damage, such as
exposed matrix collagen or von Willebrand factor (vWF) from damaged endothelial cells,
platelets are activated. Initially, the activated platelet undergoes a rearrangement of its
actin-based cytoskeleton sending out filopoida then lamellipodia, centralizing its granules
and spreading onto the damaged area. This increases the surface contact sites. The
centralized granules fuse with the OCS, resulting in the release of components from the
dense granules, α-granules, and lysosomes. Once released, these components propagate
thrombus formation and activate other circulating platelets to aggregate at the damaged
site. Finally, the granule membrane becomes part of the exterior platelet membrane,
which further increases surface contacts.

Platelet activation and aggregation for

hemostasis is a tightly regulated process, small changes in this process can result in
diseases.

Given the central role played by platelet secretion, understanding the

mechanisms of the platelet secretory machinery might be useful in controlling and/or
regulating platelet functions.

Such knowledge might direct the development of

therapeutics that could reduce spurious thrombosis and related vascular diseases.

3
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Figure 0-1-1. The Platelet Ultrastructure.
Figure 1-1. Platelet Ultrastructure.

(A) A transmission electron micrograph of a

washed murine platelet. (B) A cartoon image (made by Dr. Wangsun Choi) of the
structural components of a platelet: α-granules (blue), dense-core granules (purple), and
lysosomes (grey). Microtubules are located at each pole. The open canalicular system
(OCS) is the invaginated plasma membrane structure.
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Platelet Granule Cargo
To date, hundreds of proteins and small molecules have been shown to be
secreted from activated platelets [25]. This “secretome” can be classified by granular
source or proposed function. Dense granules are the source of small molecules, such as,
ADP, serotonin, and calcium, which are critical for platelet activation.
contain proteinaceous components.

α-Granules

Platelets also release lysosomal enzymes i.e.

cathepsins and β-hexosaminidase, which may facilitate clot remodeling. Functionally,
the “secretome” can be divided into even more categories. The most obvious class is the
adhesive proteins e.g. fibrinogen, von Willebrand Factor and thrombospondin, which are
released from α -granules and function in platelet-platelet binding. The most diverse
category is the mitogens i.e. IGF-1, VEGF, and bFGF, which promote wound healing and
vessel regrowth. Platelets also release chemokines and cytokines i.e. RANTES, IL-8, and
MIP1α/β which activate passing leukocytes and lead to a range of inflammatory
responses. This catalog suggests that platelet secretion may be pivotal in establishing the
microenvironment at a vessel wound site. Understanding more about how the secretion
process works may yield a unique tool to control the microenvironment at vascular
lesions.

Platelet and Granules Biogenesis
Platelets are produced by precursor cells, megakaryocytes, which are descended
from pluripotent stem cells in the bone marrow [1]. In the early stages of megakaryocyte
development, the premegakaryocytes differentiate from pluripotent stem cells and then
undergo endomitosis and maturation. Maturation includes four stages: megakayoblasts,
stage I; basophilic megakaryocytes, stage II; granular megakaryocytes, stage III; and
platelet-producing megakaryocytes, stage VI. At the early stages of maturation, this
progenitor cell gradually acquires distinct structures, including a demarcation membrane
system, dense tubular system, and granule precursors. Platelet-specific proteins such as
platelet factor IV (PF4), and β-thromboglobulin (β-TG) are synthesized and packaged
into α-granules at the late stages of maturation. Platelets are then produced from the
matured megakaryocytes and begin to circulate [26]. Circulating platelets live about 10
days and are primarily destroyed in the liver and spleen. Blood platelets have three types
6

of granules with distinct ultra-structure, content, and release kinetics. The ontogeny of
these granules and their relationships are unknown. Both dense core granules and αgranules originate from trans-Golgi network (TGN) elements in megakaryocytes [5]
Little is known about the lysosome biogenesis. Depending on the source, the cargo in all
three granules can be characterized as endocytic cargo, such as fibrinogen and de novo
synthesized cargo, such as PF4, β-TG, vWF, and PDGF. Most cargo are packed into
granules via one of the two routes.

SNARE Hypothesis
In 1993, Söllner et al. [27] suggested that the soluble N-ethylmaleimide-sensitivefactor (NSF) Attachment Protein (SNAP) receptors (SNAREs) are involved in
neurotransmitter exocytosis. SNAREs are membrane proteins that contain conserved
heptad repeat regions which associate to form coiled-coils. The crystal structures [28]
show that the SNARE complex is a parallel four-helix bundle with SNARE motifs
assembled into parallel, twisted coiled-coil four-helix bundles by burying the
hydrophobic residues inside. Analysis of this structure shows that it is composed of
fifteen hydrophobic layers, arranged perpendicular to the axis of the bundle, with a
central hydrophilic zero-layer containing one R- and three Q-residues connected by
highly polar bonds. Accordingly, the contributing SNARE motifs are classified as Qa-,
Qb-, Qc- and R-SNAREs [29-31] (Figure 1-2). The endosomal SNARE complex [32],
which contains syntaxin-7 (Qa), Vti1b (Vps ten interacting-1b, Qb), syntaxin-8 (Qc) and
VAMP-8 (R), has a similar structure, suggesting that the hydrophobic layers that
surround the “0” layer are highly conserved. The formation of SNARE complexes is
thought to make membrane fusion energetically favorable.

Reconstituted proteoliposome experiments confirm that SNAREs are minimally
sufficient for membrane fusion [33]. According to the original definition, SNAREs that
reside on vesicles (or granules) are referred to as v-SNAREs (also called vesicle
associated membrane proteins, VAMPs, R-SNAREs) and SNAREs that reside on target
membranes are t-SNAREs (Q-SNAREs). VAMPs and syntaxins are generally type II
integral membrane proteins with their SNARE motifs facing the cytoplasm [30]. The
7

core SNARE complex is comprised of one helical domain each from syntaxin (Qa) and vSNARE (R-SNARE) and two from SNAP-25 (Qb,c). Therefore, functional SNARE
complexes bridge the two fusing bilayers as hetero-oligomer, requiring one of each of the
Qa-, Qb-, Qc- and R-SNAREs. There are several v-SNAREs (R-SNARE): cellubrevin,
VAMP1-12, etc [34], and two types of t-SNAREs: syntaxin-like (Qa) and SNAP-25-like
(Qbc). Numerous syntaxin-like homologues have been reported (syntaxin-1 to -19) [35],
while there are only a few SNAP-25-like t-SNAREs (SNAP-23, SNAP-25, SNAP-29,
Sec9p) [34].
Although most SNAREs have a standard integral-membrane protein structure,
there are some exceptions.

SNAP-25-like t-SNAREs lack transmembrane domains

(TMD) and are generally anchored to the membrane through thiolester-linked acyl
groups. A stretch of cyteines in the linker between SNARE motifs are through to be
modified. A subset of VAMPs lacks TMD but have hydrophobic post-translational
modifications that mediate membrane anchorage. For example, Ykt6, a S. cerevisiae
VAMP, has a C-terminal CAAX box that is farnesylated [36]. Similarly, the mammalian
syntaxin-11 does not contain a TMD, but instead has a cluster of six cysteine residues,
which are predicted to anchor to the membrane through palmitoylation. Studies by using
transfected NRK cells and human B lymphocytes have demonstrated that syntaxin-11
behaves like an integral membrane protein [37, 38]. Though the hydrophobicity of these
TMD surrogates is critical for in vitro fusion of proteolipisomes [39], it not clear what
degree of modification is required in vivo.
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Modified from Jahn et al. [30]
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Figure 0-2: The Structure of SNAREs and SNAREs

Figure 1-2. The Structure of SNAREs.

Qa-SNAREs have N-terminal three-helix

bundles (called the Habc domain). The N-terminal domains of Qb-, Qc- and R-SNAREs
are represented by an oval shape.

SNARE motifs are shown as rectangles.

Transmembrane domains are shown as gray rectangles. Qbc-SNAREs represent a small
subfamily of SNAREs (the SNAP-25-like t-SNAREs), that contain one Qb-SNARE
motif and one Qc-SNARE motif.
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SNARE Machinery in Platelets
To date, four VAMPs (-2, -3, -7, -8), four syntaxins (-2, -4, -7, -11), and SNAP23, SNAP-25, and SNAP-29 have been demonstrated to be present in platelets [40-47].
Studies involving in vitro permeabilized platelet secretion assay, genetic manipulation
and ex vivo platelet secretion assays, in vivo studies, and human genetic disorders have
helped to identify many important proteins associated with platelet exocytosis. In this
thesis, we show a role for syntaxin-11. Biochemical studies have also identified potential
SNARE regulators that interact with t-SNAREs or t-SNARE complexes. Some of these
proteins have been shown to be important (i.e. Munc13-4, Rab27) [48-50] and others
have yet to be characterized (i.e. granuphilin and tomosyn), which will be described in
this thesis (i.e. tomosyn) [Figure 4-1 and Table 4-1].
Proteins interacting with t-SNAREs or t-SNARE complexes are potential SNARE
regulators. With this notion, several components have been identified, such as Munc18b,
Munc13-4, tomosyn-1, and granuphilin [Figure 4-1 and Table 4-1]. Some of them have
been shown to be important secretory regulators in platelets [48-50].

Platelet v-SNAREs
Four

v-SNAREs:

synaptobrevin/VAMP-2,

cellubrevin/VAMP-3,

TI-

VAMP/VAMP-7, and endobrevin/VAMP-8 [43-47] have been detected in platelets. For
the sake of simplicity, only the VAMP nomenclature will be used. VAMP-8 is the most
abundant v-SNARE in both murine and human platelets [46]. Oddly, VAMP-2 is almost
as abundant in murine platelets but is almost undetectable in human platelets. VAMP-3
and VAMP-7 are detected at approximately similar levels and a per platelet basis.
VAMP-3, a homolog of VAMP-1 and -2, was first identified in human platelets in
1999 by PCR and cloning [43] and reported to play a role in α-granule secretion [44]. It
was thought that VAMP-3 was required for platelet secretion since other VAMPs had not
been identified in platelets at that time and a commercial preparation of VAMP-1/2/3cleaving Tetanus toxin inhibited secretion from permeabilized platelets [44, 51].
Consistently, studies using an anti-VAMP-3 peptide antibody [52] inhibited Ca2+induced alpha-granule secretion by approximately 50%, and the cytoplasmic domain of
VAMP-3 affected both dense and α-granule secretion [45].
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Although in vitro

permeabilized platelet studies using antibodies, toxins, and peptides have potential
drawbacks such as steric hindrance by antibodies, contaminants in the commercial
preparations and cytoplasmic-domain-binding promiscuity.

It was surprising when

platelets from VAMP-3 null mice had no secretion defect [53]. These ex vivo studies
demonstrated that VAMP-3 was not absolutely required. During the analysis of VAMP-3
null platelets, VAMP-2 was detected in both human and murine platelets. Considering
that VAMP-2 is important for neurotransmitter release [54, 55], and Tetanus toxin had
affected permeabilized-platelet secretion, it could play a role in platelet secretion.
However, partial deletion of VAMP-2 (~50% reduction) had no defect on murine platelet
secretion nor did deletion of VAMP-3 and reduction of VAMP-2. These results indicated
that neither VAMP-2 nor VAMP-3 were essential for platelet secretion. VAMP-7 was
found in platelets using western blot analysis, however there was no evidence, using
antibodies and inhibitor peptides, to show that VAMP-7 is involved in platelet secretion.
VAMP-7 was first identified in epithelial cells as a TeNT-insensitive VAMP (TI-VAMP)
involved in exocytosis [56]. Its unique amino-terminal regulatory Longin domain was
thought to be involved in post-Golgi and endosomal trafficking [57]. VAMP-8, was
originally identified as an endosomal v-SNARE involved in fusion between early and late
endosomes [58], [58], but subsequent studies suggested a role in many regulatory
secretion processes [59-62]. The cytosolic domain of VAMP-8 did not have a dominant
negative effect on platelet secretion [45]. More conclusive studies by Ren at al. [46]
clearly showed that VAMP-8 is required for platelet secretion. In comparative analysis
of platelets from VAMP-3-/-, VAMP-2+/-, VAMP-2+/- /VAMP-3-/-, and VAMP-8-/- mice,
only those lacking VAMP-8 had attenuated secretion. Permeabilized VAMP-8-/- mouse
platelets further treated with Tetanus toxin showed no release; all three secretion events
were totally abolished. These findings indicate that VAMP-8 is required for normal
granule secretion though VAMP-2 and -3 do appear to compensate, in a less efficient
manner, when VAMP-8 is absent. This suggested that perhaps there is a hierarchy in
VAMP usage with VAMP-8 being the primary v-SNARE required for rapid and efficient
release and VAMP-2 or-3 play a secondary role. This ranked redundancy of v-SNARE
usage has been seen in neuroendocrine chromaffin cells from the studies of VAMP-2 KO
mice [55]. Alternatively, this differential usage could imply distinct fusion steps leading
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to release: primary granule-plasma membrane vs. granule-granule (compound) fusion
Studies by Jonnalagadda and co-workers (Jonnalagadda et al, in preparation) suggest that
granule cargo release is best described as a mixture of single and compound fusion
processes that have distinct rates. Clearly more experimentation will be required to
understand the precise kinetics of VAMP usage and granule secretion. That said, it is
clear that among the four VAMPs (-2, -3, -7, -8), VAMP-8 is the primary v-SNARE
required for platelet secretion and VAMP-2 and -3 play some less efficient compensatory
role. It is possible that such ranked redundancy in SNARE usage might be common for
many important physiological processes.

Platelet t-SNAREs
Fusogenic SNARE complex in platelets is thought to be formed by one v-SNARE
and two different t-SNAREs, which include a SNAP-25-type and a syntaxin-type.
Although reports indicate that all three SNAPs (SNAP-23, -25, -29) [5, 63] are present in
platelets, we have only detected SNAP-23 in significant quantities. This family of tSNAREs does not contain classical TMD’s but instead is anchored in the membrane via
thioester linked palmitates attached to a series of cysteines between the two SNARE
motifs. Perhaps between of the type of membrane anchor, SNAP-23 rapidly relocalizes
to lipid rafts upon platelet activation (Karim et al, in preparation).

Studies using

inhibitory antibodies and peptides in permeabilized platelets suggest that SNAP-23 is
required for all three granule secretion events [40, 41, 44, 45, 63-65].

Co-

immunoprecipitation experiments indicate that SNAP-23, in platelet extracts, can
associate into complexes with most of the platelet syntaxin (-2, -4, -11) and with at least
VAMP-3 and -8. SNAP-23 is phosphorylated upon activation, suggesting SNAP-23
might be an important link between the platelet activation signaling event and the
regulatory secretion process [45, 66]. A study by Polgar et al [45], revealed that human
platelet SNAP-23 is phosphorylated at Ser23/Thr24 and Ser61 after platelet activation by
thrombin. In murine mast cells and platelets, SNAP-23 is phosphorylated at Ser95 or
Ser120 [66]. SNAP-23 is also a substrate for calpain in activated platelets. Calpains are
calcium-dependent, non-lysosomal, neutral, cysteine proteases present in most
mammalian tissues.

Several inhibitors, i.e. calpeptin, calpastatin, and E64d, block
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SNAP-23 cleavage in heavily activated platelets [67, 68]. It is not clear what role SNAP23 cleavage plays since calpain inhibitors had limited effects on release of soluble cargo.
Given the caveats of the described experiments, it seems reasonable to conclude that
SNAP-23 is important for platelet secretion. Studies with knockout murine strains or
humans with SNAP-23 defects will be required to confirm this conclusion. However,
global deletion of SNAP-23 is embryonic lethal and attempts to make condition deletion
strains have been unsuccessful [69] (Dr. Roche, NCI, personal communication with Dr.
Whiteheart).
In addition to the SNARE motif, syntaxins contain an additional N-terminal
helical domain (the Habc domain), which is thought to serve a regulatory and/or autoinhibitory function. Initial studies focused on syntaxin that had predominantly plasma
membrane localization in nucleated cells.

Syntaxin-2 and -4 were first detected in

platelets but syntaxin-1, -3, and -5 were not [5, 64]. Both syntaxin-2 and -4 had been
shown to be involved in other secretion events [38, 70-72] and studies using
permeabilized platelets suggested that syntaxin-2 was important for all three granule
release events while syntaxin-4 played a role in only alpha granule and lysosome release
[40, 41, 44]. These early data suggested that syntaxin-2 and -4 was important for platelet
secretion. Strikingly, platelets from mice lacking either syntaxin-2 and -4 alone or
together showed no secretion defect [Chapter 3, this thesis]. As with the studies with
VAMPs, these conflicting data showed that syntaxin-2 and -4 are not required for
secretion from mouse platelets. As shown for the VAMPs, using antibodies as inhibitors
can lead to ambiguous results. Considering that the syntaxin-2 polyclonal antibody used
as an inhibitor in the permeabilized platelets [40, 41] was generated against full length
recombinant protein, it is possible that this antibody was not as isoform-specific as was
thought. The experiments in this thesis directly address the question of which syntaxin
isoform(s) is/are required for platelet secretion.
Syntaxin-7 is localized to an intracellular compartment instead of the plasma
membrane in nucleated cells [38] and thus was not considered a likely candidate to
mediate platelet exocytosis. Although syntaxin-7 was found in platelets over 10 years
ago [40], the role of syntaxin-7 is still unclear. Introducing specific syntaxin-7 antibodies
into permeabilized platelets had no effect on any of the three granule secretion events
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[42].

This is the only data to suggest that syntaxin-7 is not required for platelet

exocytosis.
Finally, proteomics studies were the first to show that syntaxin-11 is present in
platelets [73]. Syntaxin-11 is a unique member of syntaxin family which has the Habc
and SNARE motifs but lacks a classical TMD. It appears to be anchored to membranes
via, yet to be defined modifications of its C-terminal cysteine residues [74] [37].
Syntaxin-11 is associated with late endosomes and the trans-Golgi network in Hela cells
[37]. Interestingly syntaxin-11 mutations are associated with Familial Hemophagocytic
Lymphohistiocytosis type 4 (FHL4). FHL4 is a rare autosomal recessive disorder of
immune dysregulation associated with uncontrolled T cell and macrophage activation.
Patients usually present with fever, hepatosplenomegaly, and cytopenias. Syntaxin-11
deficient NK-cells exhibit a defect in cytotoxic granules degranulation .ndicating that
syntaxin-11 could be involved in fusion to the plasma membrane. However, other studies
show that activation of syntaxin-11 deficient T-cells with IL-2 does restore degranulation
[75, 76]. Comparative analysis of wild type and syntaxin-11 deficient CD8+ T-cells
suggested that syntaxin-11 affects the granule-granule fusion step before final fusion with
the plasma membrane [76]. These data suggest that syntaxin-11 is important for T-cell
degranulation although its mode of action is not clear. Moreover, syntaxin-11 also has
been shown to play a negative regulatory role in macrophage [77]. Syntaxin-11 regulates
Vti1b-containing SNARE complex formation by directly binding to Vti1b (Qb-SNARE),
thus controlling late endosome to lysosome fusion.

Considering that cytotoxic T-

lymphocyte (CTL) and natural killer (NK) cell require syntaxin-11 for membrane fusion
and degranulation, this negative role for syntaxin-11 in macrophage suggests that the
function of syntaxin-11 may be tissue- or SNARE-specific. Further studies are required
to demonstrate the different roles of syntaxin-11 in these immune cells. Work in this
thesis shows that syntaxin-11 is important for platelet exocytosis (Chapter 3).

SNARE Regulators in Platelets
Regulated platelet secretion happens only in respond to external signals, but how
these signaling pathways are coupled to the SNARE machinery is still not clear. Based
on the number of binding partners identified and the presence of the Habc domain, it has
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been thought that most regulation of SNAREs is through the syntaxins. Very few VAMP
and SNAP-23/25 regulators have been identified.

In addition, post-translational

modifications, such as phosphorylation of SNAREs and SNARE regulators could provide
links from signaling to secretion.

Several potential SNARE regulators have been

identified in platelets and most are associated with t-SNARE heterodimers or t-SNARE
containing complexes. We will discuss what is known about the following: Munc18b,
Munc13, granuphilin, and tomosyn.

Munc18s
Munc18s belong to the evolutionally conserved Sec1/Munc18 (SM) family, which
is a critical component of the secretory machinery [30]. There are three mammalian
Munc18 isoforms and all (Munc18a, b, and c) have been detected in human and murine
platelets by immunoblotting and/or PCR [47, 63, 78]. It has been thought that different
SM proteins are required for specific secretion steps through their interactions with
specific syntaxins. Munc18a is almost exclusively expressed in neurons where it binding
to syntaxin-1 while Munc18c is ubiquitous expressed in other tissues and appears to
interact with syntaxin-4 [79]. In platelets, Munc18a was shown to interact with syntaxin2, Munc18c with syntaxin-4, and Munc18b was found associated with SNARE
complexes [47] and with syntaxin-11 (Al Hawas et al. in preparation). Early studies
suggested that Munc18c phosphorylation and Munc18c/syntaxin-4 complex formation
could be important for platelet secretion [63, 78]. Monoclonal antibodies that disrupted
Munc18c/syntaxin-4 complexes had a positive effect on release from permeabilized
platelets [63]. Further, introduction of peptides, based on conserved regulatory domain
of Munc18s, peptides into permeabilized platelets inhibited Ca2+-stimulated release from
all three granule release events [47]. These in vitro studies suggest that Munc18s was
important for platelet secretion. Surprisingly, platelets from Munc18c heterozygous mice
(with a ~50% reduction in Munc18c) exhibited normal stimulus-induced release [80].
Double deletion of Munc18c died either in utero or within 6 hours after birth [81]. Based
on that the syntaxin-4 level is reduced ~50% in Munc18c heterozygous mouse platelets, it
is consistent with Munc18c being the chaperone for syntaxin-4. The association between
Munc18c and syntaxin-4 is required for the stability of both proteins [47, 80]. Although
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in vitro studies [47] suggest Munc18c plays a role in platelet secretion, the lack of
secretion defect could be attributed to functional compensation by other Munc18s.
Munc18a levels are low in human and murine platelets and though it is phosphorylated
and binds syntaxin-2 [47, 63], it is not clear if it plays any role in exocytosis. The most
promising candidate for a functional Munc18 in platelets is Munc18b. Munc18b is the
most abundant isoform and it was found to interact with syntaxin-11. Munc18b was also
detected in pull-down experiments using SNARE complexes [47] and t-SNARE
heterodimers (Figure 4-1A and Table 4-1). Most importantly, Sandrock et al [50] and
our unpublished data (Al Hawas et al. in preparation) showed that Munc18b deficient
platelets from Familial Hemophagocytic Lymphohistiocytosis type 5 (FHL5) patients
have a robust secretion defect suggest that Munc18b is required for platelet secretion.
The fact that heterozygous patients have a partial secretion defect might suggest that
Munc18b is a limiting factor in the secretion process remains to be tested. Syntaxin-11
levels were affected in these patients.

Rab Proteins
The Rab subfamily of small Ras-like GTPase includes over 60 members in
mammals and regulates intracellular membrane traffic [82]. Several Rab proteins have
been identified in platelets, such as Rab3B, Rab4, Rab6, Rab8, and Rab27 [83-86]. It is
generally thought that different Rabs regulate different secretion routes through
associations with specific effectors.

It has been shown that Rab6 and Rab8 are

preferentially targeted to the plasma membrane and α-granules [83]. Studies using a
dominant negative mutant of Rab4 suggested that Rab4 regulates α-granule but not dense
granule secretion [85]. Biochemical studies have shown that the majority of Rab27 is
associated with dense granules while a small portion is located on the plasma membrane
[49]. Rab27ab are involved in both dense granule biogenesis in megakaryocytes and in
platelet secretion. Deficiency of Rab27a in ashen mice exhibits “ghost” dense granules
(with normal number but defective contents) [84] while loss of Rab27b shows around
50% reduction in both dense granule number and serotonin content [86] with normal αgranule contents and secretion. This data suggest that the Rab27 family is critical for
dense granule biogenesis, but not important for α-granule and lysosome biogenesis.
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Further Rab27 double KO murine platelets display more severe defect in serotonin
secretion than single Rab27b KO, indicating that Rab27a can partially compensate for
dense granule secretion [86]. The exact role of Rab27 in dense granules remains unclear.
Presumably the distinct functions of Rab27 require different effectors. The fact that one
of Rab27b effectors, Munc13-4, is required for platelet secretion [48, 49] could explain
why Rab27b plays a role in exocytosis. It is also possible that Rab27s interacts with
unknown factors, which are important for dense granule package and trafficking. On the
other hand, Munc13-4 is not required for granule biogenesis since there is no granule
defects observed in Munc13-4 depleted murine platelets [48]. Further exploration of the
mechanisms for Rab27 function in platelet secretion will clarify whether different granule
secretion requires specific sets of Rab proteins, effectors, or even secretory machinery
components in platelets.

Munc13s
The Munc13 family has four members: Munc13-1, -2 and -3 are expressed in
neuron tissue; Munc13-4 is ubiquitously expressed. Munc13s are widely believed to be
key vesicle priming factors. The strongest evidence is from genetic ablation of both
Munc13-1 and Munc13-2 in neurons. This completely abolishes synaptic vesicle priming
and release [87, 88]. Munc13-4 was first identified in platelets as a Rab27a binding
partner [49] and is essential for platelet secretion. Mice lacking Munc13-4 have a severe
bleeding diathesis and the release from dense granules is totally abolished while release
from α-granules and lysosomes is severely impaired [48]. This shows that Munc13-4
mediates at least one step that is uniquely required for rapid dense granule release, a step
that is also critical for hemostasis in vivo. The residual secretion from α-granules and
lysosomes could be due to compensation by another Munc13 family member considering
that both Munc13-1 and Munc13-4 can interact with Munc18a/syntaxin-2 complex in
platelets (Figure 4-8).

Compared to other Munc13s, Munc13-4 does not contain a

diacylglycerol-binding C1 domain, but does have two calcium/phosphatidylserinebinding C2 domain (C2A and C2B) and Munc Homology Domains (MHD). Mutations
in the MHD domain or deletion of C2B result in FHL3 in humans [89]. Recombinant
Munc13-4 lacking C2B potently inhibits platelet secretion from permeabilized cells [48]

18

suggests that both the MHD domain and C2B domain are important for its function. It is
possible that the MHD domain is required for interactions with important secretory
machinery components while C2B is important for anchoring to the plasma membrane or
regulating membrane fusion in response to Ca2+ signaling. Identification of key Munc134 interacting partners will be an important step in understanding the SNARE complex
formation and membrane fusion upon stimulation.

Clearly Rab27 is a possible

candidates as is another Rab27 effector called granuphilin since they are present in
platelets.. Another possible candidate Munc13-4 effector is DOC2α because it have been
shown to interact with other Munc13 isoforms. In summary, Munc13-4 is an essential
component in dense granule secretion pathway. Further exploration of its mechanism
will not only identify new elements of the secretory machinery, but also clarify whether
secretion of different granules requires specific sets of secretory machinery in platelets.

Synaptotagmin-Like Proteins (Slps):
Slps possess a C-terminal synaptotagmin-like domain with C-terminal tandem C2
domains (putative Ca2+-dependent phospholipid binding sites) and an N-terminal Rab27binding domain. There are five Slp isoforms (Slp1 to 5) in mammals [90]. Slp1 and Slp4
(or granuphilin) are present in platelets [91].

Studies by Neumuller et al [91]

demonstrated that purified Slp1 can partially inhibit dense granule secretion from
permeabilized platelets. Endogenous Slp1 forms a trimetric complex with Rap1GAP2
and Rab27, suggesting Slp1 is a Rab27 effector that regulates dense granule secretion.
Though little is known about granuphilin in platelets, it has been well studied in other
secretory cells. Granuphilin is abundantly expressed in beta cells and considered to be
essential for the stable attachment of insulin granules to the plasma membrane where it
acts by linking Rab27a on the granule membrane with the syntaxin-1a/Munc18a complex
on the plasma membrane [92]. Loss of granuphilin causes a decrease in docked granules
in these cells [93]. Granuphilin can bind to both syntaxin-1a and Munc18a [94-96]. The
enhanced insulin secretion from granuphilin deficient beta cells [97], despite the docking
defect, argues for it being a negative regulator. Granuphilin could have a negative effect
on a step just prior to the final fusion reaction. It is possible that a local signal such as
increased [Ca2+]i after stimulation may cause dislocation of granuphilin from the
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Munc18a-syntaxin-1a complex and allow SNARE assembly. This is consistent with the
ability of both Slp and Munc13 families binding Rab27 and containing C-terminal Ca2+
binding C2 domains.

Tomosyn-1
Tomosyn-1 belongs to a family of WD-40 repeat containing proteins associated
with exocytosis including Sro7/Sro77 in yeast, Tom1 in c.elegans, amisyn and lethal
giant lavea (lgl) in mammalian [98-101]. Two genes, tomosyn-1 and tomosyn-2, were
found in mammalian but alternative splicing can produce a total of seven isoforms [102,
103].

Little is known about the exact role of tomosyn-2 in secretion [102] while

tomosyn-1 is well studied in neuron and endocrine cell exocytosis. Tomosyn-1 has three
isoforms (b-, m-, s-) and has several predicted phosphorylation sites (Figure 1-3). mtomosyn-1 was originally identified as a syntaxin-1 binding partners from rat brain tissue
cell [104]. The s-tomosyn-1 and m-tomosyn-1 isoforms are enriched in synapse-specific
domains while b-tomosyn-1 is ubiquitously expressed [105]. Structurally, mammalian
tomosyn-1 contains an N-terminal WD40 repeat, a small highly variable linker region,
and a C-terminal R-SNARE (v-SNARE) motif [103]. Both the R-SNARE motif and Nterminal WD40 repeat have been shown to inhibit secretion from PC12 cells [106] and
neurons [107].

Thus tomosyn-1 has been thought as a negative regulator for

neurotransmitter release events. Consistently, deletion of tomosyn-1 enhances secretion
[107]. Over-expression of tomosyn-1, in PC12 cells, reduces the ready-release pool and
resident time of secretory vesicles [108].

This observation is consistent with the

hypothesis that tomosyn-1 functions by disrupting vesicle priming. It has also been
suggested that the N-terminal WD-40 domain may catalyze the formation of
nonfunctional SNARE complexes [109] or through its loop region by interactions with
unknown factors [110].

Alternatively, the SNARE domain could block v-SNARE

binding to t-SNAREs, thus inhibiting membrane fusion and exocytosis.

Post-

translational modifications such as phosphorylation have been suggested to regulate this
process [111].

Despite these data, the exact mechanism of tomosyn-1 as negative

regulator is still unclear.
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Figure 0-3. Tomosyn-1 isoforms in rat and human.
Figure 1-3. Tomosyn-1 Isoforms in Rat and Human. The domain structure of the
three isoforms of Tomosyn-1. b-tomosyn-1 is a full length isoform. m-tomosyn-1 skips
exon 20 and 21, and s-tomosyn-1 skips exon 20-22. The WD40 repeats are in cyan, RSNARE coiled-coil motif is in blue, and variable region is in gray. The bottom panel
shows the predicted phosphorylation sites in the variable region. The labels represent
sites of phosphorylation by PKA as A, PKC as C, PKG as G, casein kinase II as K, GSD3
and DNAPK as X.
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Although data supports a negative role for tomosyn-1, it has also been shown to
function permissively in exocytosis. Over-expression of tomosyn-1 in SCG neurons
enhances release [111]. The long term potential (LTP) of mossy fiber without tomosyn-1
is not inhibited. Moreover, depletion of both Sro7/Sro77 [100] inhibits secretion while a
deletion of tomosyn-1 in β-cell causes a secretion defect [112].

In light of our

observation that tomosyn-1 can form a complex with the t-SNARE heterodimers,
Munc18C [113], and Munc18b [Figure 4-1], tomosyn-1 could control secretion by
activating t-SNARE complex and thus facilitating t-/v-SNARE complex formation.
Experiments in this thesis address the role of tomosyn in platelets.

Cytoskeletal Polymerization and Platelet Secretion
Upon vascular damage, human platelets become activated and dramatically
change their shape through cytoskeleton rearrangement.

This precedes granule

centralization and content release mediated by membrane fusion [114]. Disruption of the
actin cytoskeleton by latrunculin A or inhibition of actin polymerization with
cytochalasin E [115] inhibits alpha-granule secretion induced by different agonists. This
connects actin polymerization with platelet secretion. In a recent paper, Woronowicz et
al. [115] show that the actin cytoskeleton can associate with t-SNAREs and actin
polymerization is important for alpha-granule secretion. Further interactions between the
platelet cytoskeleton and the secretory machinery are yet to be identified.

Platelet Activation and Secretion
Platelet activation occurs through signaling cascades [116]. Different agonists
bind to the diverse platelet surface receptors, ultimately leading to common intracellular
signaling events that activate a phospholipase C (PLC). Activated PLC catalyzes the
hydrolysis of phosphatidylinositol 4,5-bisphosphate to release inositol trisphosphate (IP3)
and diacyglycerol (DAG), which activate calcium mobilization and protein kinase C
(PKC), respectively. The hallmark of platelet activation is activation of integrin αIIbβ3 to
mediate aggreagation [116-118]. Platelet secretion is also one of the end steps of these
signaling cascades, but how they are connected and how secretion is regulated is still not
clear. One hypothesis is that post-translational modification plays an important role.
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Phosphorylation, S-nitrosylation, or sumoylation of SNARE proteins or their regulatory
proteins has been suggested to be important. Another possibility is that secondary signal
molecules, such as calcium, may remove inhibitory proteins or activate SNAREs.
Calcium is clearly an important factor in the activation of the secretory machinery, and it
alone can initiate release from permeabilized platelets. Calcium influx can also regulate
actin-binding proteins and caused dissolution of the cortical F-actin, which can affect
granule localization and and give granules freer access to exocytic sites on the plasma
membrane. Depolymerization of cortical F-actin or polymerization of F-actin, or myosin
Va might mediate the recruitment of secretory granules near the plasma membrane (OCS)
since granule centralization is observed.

Thesis Overview
Understanding the molecular mechanism of platelet exocytosis requires the
identification and characterization of the important core SNARE proteins and their
regulatory molecules.

The demonstration that VAMP-8 is the primary v-SNARE

required for platelet secretion and that platelet secretion is mediated by SNARE
complexes, led to the central hypothesis of this thesis; platelet secretion and hemostasis
are controlled by primary t-SNAREs and t-SNAREs regulators. The focus of this thesis
is to determine the primary t-SNARE(s) required for platelet secretion and the t-SNARE
regulating proteins. The answer to this question will not only define the core SNARE
components required for platelet secretion, but also expand the possible ways to regulate
platelet function and hemostasis.
The original anti-syntaxin-2 polyclonal antibody was found to cross react with
syntaxin-11 and it also immunoprecipitated syntaxin-11 from platelet extracts. This
partially explains why syntaxin-2 antibodies inhibited permeabilized platelet secretion
while syntaxin-2/4 double KO mice have no secretion defect. The syntaxin-11 deficient
platelets from a FHL4 patient showed significant defects in dense granule and α-granule
secretion while lysosome secretion was partially. The aggregation defect from these
same platelets is likely caused by an ADP release defect, which is required for a second
wave of aggregation through activation of integrin αIIbβ3. Taken as a whole these data
show that syntaxin-11 is required for platelet secretion.
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A specific role for tomosyn-1 in platelets has also been studied. Tomosyn-1 was
first identified in platelets by mass spectrometry as a specific binding partner of
recombinant t-SNARE complexes [Chapter 4]. Additionally, we showed that tomosyn-1
is phosphorylated and associated with SNAP-23 in both resting and activated platelets.
The role of endogenous tomosyn-1 has been investigated using tomosyn-1 KO mice.
Tomosyn-1 deficient platelets have a normal aggregation phenotype, but a partial
secretion defect. The partial nature of the defect suggests that other members from
tomosyn-1 family may play a compensatory role when tomosyn-1 is missing. Most
interestingly, tomosyn-1 deficient mice display a robust bleeding phenotype in two in
vivo thrombosis models: prolonged bleeding times and impaired thrombosis tail bleeding
and FeCl3 carotid injury. These data demonstrate tomosyn-1 is important for hemostasis
and thrombosis.

Copyright © Shaojing Ye 2012
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Chapter Two
Materials and Methods

Materials
Antibodies
Anti-syntaxin-2, -4, -7, and SNAP-23 polyclonal antibodies were generated in the
Whiteheart laboratory as described previously [40, 41].

Anti-syntaxin-11 rabbit

polyclonal antibody (110113) was purchased from Synaptic System GmbH (Gottingen,
Germany) while murine monoclonal antibody (611282) was obtained from BD
Transduction Laboratories (San Jose, CA).

Anti-Munc18a (clone131.1) was from

Synaptic System (Goettingen, Germany). Anti-Munc18b antibody (sc-14563) was from
Santa Cruz Inc. (Santa Cruz, CA). Anti-Munc18c polyclonal antibody was produced in
the Whiteheart laboratory as described previously [47]. Anti-synaptobrevin/VAMP-2
monoclonal antibody (CL69.1), anti-endobrevin/VAMP-8 polyclonal antibody, anti-ratMunc13-1 monoclonal antibody (CL266B1), and anti-cellubrevin/VAMP-3 polyclonal
antibody were generous gifts from Dr. Jeffery Pessin (Albert Einstein College of
Medicine). Anti-TI-VAMP/VAMP-7 monoclonal antibody (TG158.2) was a generous
gift from Dr. Thierry Galli (Institut Pasteur, Paris, France). Polyclonal rabbit-anti-human
VAMP-8 antibody were generated in our laboratory using recombinant versions of the
cytoplasmic domain of human VAMP-8 (1-73 aa) and the Longin domain of human
VAMP-7 (1-120 aa) as antigen, respectively. Anti-RabGDI polyclonal antibody was
generated in our laboratory by Dr. Tara Rutledge using recombinant RabGDIα as
antigen.

Anti-tomosyn-1 monoclonal antibody (611296) was purchased from BD

Transduction Laboratories (San Jose, CA) while anti tomosyn-1 polyclonal antibody (H55, sc-98350) was from Santa Cruz Inc. (Santa Cruz, CA). Anti-Munc13-4 monoclonal
antibody (designated as Munc13-4 mAb C) was also generated using the domain C as
antigen as generous gift from Dr. Christian Wimmer (Basel Institute for Immunology,
Basel, Switzerland). Anti-human PF4 monoclonal antibody was obtained from R&D
Systems (R&D Systems, Minneapolis, MN). Anti-human LAMP-1 monoclonal antibody
was obtained from the Developmental Studies Hybridoma Bank (University of Iowa,
Iowa City, IA). Anti-fibrinogen monoclonal antibody was purchased from Innovative
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Research (Southfield, MI). The monoclonal anti-phospho-tyrosine (pY) antibody (4G10)
was from Upstate (Lake Placid, NY). Fluorescein isothiocyanate (FITC)-conjugated
PAC-1 (recognizes activated αIIb/β3 complex) and phycoerythrin (PE)-conjugated antihuman CD41a (integrin αIIb) monoclonal antibody were purchased from BD Biosciences
(San Jose, CA).

FITC-labeled anti-human P-selectin monoclonal antibody (AK-4),

FITC-conjugated PECAM1 (553372), and FITC-conjugated anti-murine P-selectin
(553744) were from BD PharmingenTM (BD Bioscience, San Jose, CA).

FITC-

conjugated anti-murine GPVI (M011-1), FITC-conjugated GPIbbeta (M050-1), PEconjugated GPIIb/IIIa (M023-2, active form) were purchased from Emfret Analytics
(Germany). Anti-phosphotyrosine (clone 4G10) monoclonal antibodies were purchased
from Upstate Biotechnology (Lake Placid, NY).

Anti-integrin β3 rabbit polyclonal

antibody was obtained from Cell Signaling (Danvers, MA). For the sandwich EnzymeLinked ImmunoSorbent Assay (ELISA) of human and murine PF4, two sets of paired
antibodies were used: for human PF4, a monoclonal anti-human PF4 antibody was used
as the capture antibody (R&D systems) while a biotin conjugated rabbit-anti-human PF4
polyclonal antibody was used as the detection antibody (Leinco Technologies Inc., St.
Louis, MO); for murine PF4, a monoclonal, anti-murine PF4 antibody (R&D systems)
was used as the capture antibody to bind murine PF4 while a biotin conjugated rabbitanti-murine PF4 antibody was used as the detection antibody (R&D systems). Alkaline
phosphatase conjugated secondary anti-murine, anti-rabbit, anti-sheep, and anti-goat IgGs
were from Sigma. FITC or TexasRed conjugated anti-murine, anti-rat and anti-rabbit
IgGs were purchased from Vector Laboratories (Burlingame, CA). HRP conjugated
streptoavidin was from R&D systems.

General Reagents
Apyrase, benzamidine, poly-D-lysine, type I bovine plasma fibrinogen,
glutathione-conjugated agarose, 2-methyl-2-butanol, 2,2,2, tribromoethanol, tetramethyl
rhodamine isothiocyanate (TRITC)-conjugated phalloidin, and Ferric chloride (FeCl3)
were obtained from Sigma (St Louis, MO). Ortho-[32P]-phosphoric acid was purchased
from MP Biochemicals Inc. (Irvine, CA). HisProbeTM-HRP and BCATM Protein Assay
kit were purchased from Pierce (Rockford, IL). Complete, EDTA-free protease inhibitor
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cocktail was obtained from Roche (Indianapolis, IL). Acid citrate dextrose (ACD) blood
collection tubes (BD Vacutainer) were purchased from BD Diagnostics (Sparks, MD).
Formaldehyde (37%) and glutaraldehyde (70%) were purchased from Electron
Microscopy Sciences (Hatfield, PA). Type I collagen (equine tendon), human plasma
thrombin, and ADP were purchased from Chrono-log (Havertown, PA). Convulxin, a
snake venom toxin, was purchased from Centerchem Inc. (Norwalk, CT). A23187, Ca2+
ionophore, was obtained from Calbiochem (San Diego, CA).

Thrombin-activated

receptor peptide (known as PAR4 peptide, AYPGKF) was purchased from Anaspec (San
Jose, CA). Whatman filter paper (VWR, San Francisco, CA), 1 mm disc shape was used.

Methods

Murine Strains, Genotyping, and FHL4 Patient
Epimorphin/Syntaxin-2-/- Mice (Syntaxin-2 KO Mice)
Epimorphin/Syntaxin-2+/- mice on a C57/BL6 background were kindly provided
and generated by Dr. Deborah C. Rubin (Washington Univ. School of Medicine) [119].
The mutant mice were maintained by crossing with C57/BL6 mice. Murine genomic
DNA was extracted from murine tail. Genotyping was performed using primers:
For the wild type gene:
forward primer: 5’-GACAGTGTGTTAACTAGTCAAGC-3’
reverse primer: 5’TTAGATTCCCTCCTAGAGACGC-3’
For the mutated gene:
forward primer: 5’-GACAGTGTGTTAACTAGTCAAGC-3’
reverse primer: 5’-GGACACGCTGAACTTGTGGC-3’
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 35 cycles at (94
°C for 1 min, 60 °C for 0.5 min, 72 °C for 3.5 min) and 1 cycle at 72 °C for 10 min.
Syntaxin-4flox/flox/PF4-Cre+ Mice (Syntaxin-4 KO Mice)
Syntaxin-4flox/flox mice on a C57/BL6 background were kindly provided by Dr.
Jeffery Pessin (Albert Einstein College of Medicine). Genotyping was carried out with
two sets of reactions.
For the LoxP site:
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forward primer, 22F: 5’-GTTGAGGCAGGTGAGAAACC-3’
reverse primer, 25R: 5’-ATCACCAAGAGGGCTGAAGA-3’.
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 30 cycles at (94
°C for 1 min, 60 °C for 1.0 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min.
For the neo cassette:
forward primer, 58F: 5’-AGCCCAGTTGCTGGTGTATC-3’
reverse primer, 55R: 5’-AGGAGGAAGAGGTGGAGGAG-3’.
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 30 cycles at (94
°C for 1 min, 60 °C for 1.0 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min.
PF4-Cre+ mice were kindly provided by Dr. Radek Skoda (University Hospital
Basel, Switzerland). Genotyping was performed using the following primers.
For the wild type gene:
forward primer, 5’-CCCATACAGCATACCTTTTG-3’
reverse primer, 5’-GAAACAACAGGCCCAGAAGC-3’
For the Cre transgene:
forward primer, 5’-CCCATACAGCATACCTTTTG-3’
reverse primer, 5’- TGCACAGTCAGCAGGTT-3’).
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 30 cycles at (94
°C for 1 min, 50 °C for 1.0 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min.
Syntaxin-4 platelet specific syntaxin-4 deletion mice (syntaxin-4 KO mice) were
generated by a cross of the above two murine strains.
Syntaxin-2-/-/Syntaxin-4flox/flox/Cre+ (Syntaxin-2/4 Double KO Mice)
Syntaxin-2/4 double KO mice were generated by crossing above three strains:
syntaxin-2 KO mice, Syntaxin-4flox/flox mice, and PF4-Cre+ mice.
Tomosyn-1-/- Mice
Heterozygous Embryos of tomosyn-1 were kindly provided by Dr.
Yoshimi Takai (Kobe University Graduate School of Medicine, Japan) and Dr. Jun
Miyoshi (Osaka Medical Center, Japan).

The genetic background of tomosyn-1

knockouts is the mixture of 129 50%, C57BL6 25% and DBA2 25%. The Embryos were
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recovered into live mice by the Jackson Laboratory. Genotyping of tomosyn-1 KO mice
was performed by PCR using primers: for KO mice:
forward primer, 5'-GGGCGCCCGGTTCTTTTTGTC-3'
reverse primer, 5'-GCCATGATGGATACTTTCTCG-3'
for wild type mice:
forward primer, 5'-TTCTGCTCCCCGCTGCTCCTT-3'
reverse primer, 5'-TCCCCGCTCCCTTCACCTTGC-3'.
PCR conditions were as follows: 1 cycle at 94 °C for 7 min, then 40 cycles at (94
°C for 1 min, 57 °C for 1 min, 72 °C for 1.5 min) and 1 cycle at 72 °C for 10 min. The
expected PCR products are 224 bp for tomosyn-1 KO and 300 bp for the wild type.
All procedures and usage of mice were approved by the DLAR at the University
of Kentucky.

Syntaxin-11 Deficient Platelets from FHL4 Patient
15 mL of whole blood was collected from a FHL4 patient who displayed bleeding
problems and a profound defect of NK cell degranulation (Dr. Filipovich Cincinnati
Children’s’ Hospital, personal communication with Dr. Whiteheart). The platelets from
the patient were isolated using standard procedures. The genotype of the patient was
determined by standard sequencing methods: Allele 1 - 173T>C (D58R), Allele 2 173T>C (D58R). All procedures were approved by the IRBs at the Cincinnati Children’s
Hospital and at the University of Kentucky.

Platelet Preparation from Mice and Human Blood
Mice were euthanatized by CO2 inhalation. After the heart was exposed, a 1 mL
syringe filled with ~100 µL of 3.8% sodium citrate and attached to a 26 G needle was
used to collect blood from the right ventricle.
In order to accurately measure the individual murine platelets and erythrocytes,
whole blood without dilution from syntaxin KO mice and wild type mice were counted
with Hemvet (DREW Scientific Inc., Oxford, Connecticut) for all three blood cells at the
same time.
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The citrated blood was then mixed with an equal volume of PBS and adjusted to
0.38% sodium citrate final concentration. Human blood were collected into Acid citrate
dextrose (ACD) blood collection tubes and then diluted with an equal volume of PBS.
Both murine and human blood was first centrifuged at 250 × g for 10 minutes (min) at
RT. The Platelet Rich Plasma (PRP) was carefully removed (avoiding the buffy coat
between the PRP and the red blood cell layer). After adding 100 ng/mL prostaglandin I2
(PGI2, Sigma) for 5 min at RT, the platelets were harvested by centrifugation at 900 × g
for 15 min. The pellet was gently resuspended in HEPES/Tyrode’s Buffer (10 mM
HEPES/NaOH, pH 7.4, 5.56 mM glucose, 137 mM NaCl, 12 mM NaHCO3, 2.7 mM
KCl, 0.36 mM KH2PO4, 1 mM MgCl2) containing 0.3 U/mL apyrase (Sigma).

Measurement of Secretion from Intact Murine Platelet
Washed platelets were labeled with 2 µCi/mL [3H]-5-HT (Perkin-Elmer Cetus
Life Sciences, Boston, MA) for 45 min at 30°C.

After washing twice with

HEPES/Tyrode’s Buffer (pH 7.4) in the presence of 0.3 U/mL apyrase, the platelets were
resuspended with HEPES/Tyrode’s Buffer (pH 7.4).

Platelet concentration was

determined by Z2 Coulter particle counter and size analyzer (Beckman Coulter,
Fullerton, CA) and adjusted to 2.5 × 108 platelets/mL. A final concentration of 0.7 mM
CaCl2 was added to the platelet suspension before stimulation.
For thrombin titrations, a concentration series of thrombin (Chrono-Log,
Havertown, PA) was added to stimulate platelets (50 µL of resuspension) at RT.
Reactions were stopped by adding a twofold excess of hirudin (Sigma) and then placed
on ice. For the time course experiments, 0.05 U/mL of thrombin was added for the
indicated time periods, and 0.1 U/mL of hirudin was added to stop the reaction. When all
reactions were finished, the samples were subjected to centrifugation at 13,000 × g for 1
min. The supernatant was recovered to another tube. The pellet was lysed with an equal
volume of lysis buffer (PBS, pH 7.4, 1% Triton X-100) for 1 hr on ice. An equal volume
of the supernatant and the pellet was assayed for the three granule cargo markers: [3H]-5HT for dense core granules, PF4 for α-granules. and β-hexoaminidase for lysosomes, as
described previously [53].

For the dense core granule release assay, 25 µL of the

supernatant or the pellet was added to 3 mL of scintillation cocktail solution. The
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samples were analyzed using a Tri-Carb 2100TR liquid scintillation analyzer (Beckman,
Fullerton, CA). For α-granule secretion, a sandwich ELISA method was used to detect
the specific α-granule marker, PF4. This ELISA assay was performed according to the
manufacturer’s instruction (R&D systems).

To assay for lysosomal secretion, the

enzymatic activity of β-hexosaminidase was measured. Six microliters of supernatant
and 3 µL of the pellet samples was added to 100 µL of citrate-phosphate buffer (53.4 mM
citric acid, 93.2 mM Na2HPO4, pH 4.5) containing 10 mM p-nitrophenyl-N-acetyl-β-Dglucosaminide. The reactions were incubated at 37°C in a sealed, 96 well plate for 18 hrs
and stopped with 100 µL of 0.08 N NaOH. The optical density of each well was
measured at 405 nm using a Biotek Elx808 plate reader (BioTek Instruments Inc.,
Winooski, VT). The percent release for each marker at each data point was calculated by
using the supernatant fraction divided by the supernatant plus the pellet fraction (total).

Platelet Aggregometry
Washed platelets or PRP were centrifuged at 13,000 rpm for 1 minute in a
tabletop centrifuge to obtain platelet-poor plasma (PPP) which was used to set the
baseline. Platelet suspension (500 µL) was warmed at 37°C in a siliconized glass cuvette
(Chrono-log, Havertown, PA) containing a metal stir bar (Chrono-log) with stirring (800
rpm) using a Model 460Vs Lumi-Dual aggregometer (Chrono-log) for 2-3 minutes.
Agonists were added to initiate platelet activation. Aggregation traces were monitored
using a Model 810 Aggro/Link computer interface and Aggro/Link software (Chronolog).
Platelet ATP Release
ATP release from platelet dense-core granules was monitored by the
luciferin/ATP-mediated luminescence using an aggregometer. Washed platelets (475
µL) were preincubated with 25 µL of Chrono-Lume reagent (Chrono-log) containing
luciferin and luciferase for 2 minutes at 37°C. Addition of thrombin, collagen (ChronoLog), or A23187 (Calbiochem, La Jolla, CA), initiated ATP release from platelets, ATPdriven activation of luciferase, followed by production of luciferin which were monitored
by absorption at 560 nm. Luminescence traces along with aggregation were using the
same interface and software.
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Flow Cytometry Analysis
Washed murine or human resting or thrombin activated platelets (20 µL) at a
concentration of 1 × 108 platelets/mL were incubated with 2.5 µL FITC-conjugated or
PE-conjugated antibodies for 15 minutes at RT. Platelet samples were then fixed with
700 µL of 0.5% formaldehyde in phosphate-buffer saline (PBS) at RT for 30 minutes.
Samples for flow cytometry were moved in a polystyrene FalconTM tube (BD
Biosciences, San Jose, CA). Fluorescent intensity was measured using FACScanTM flow
cytometer (BD Biosciences). Platelet population was detected by adjusting the voltages
for forward light scattering (FSC; E-01/linear) and side light scattering (SSC; 450/linear).
Fluorescent intensity was optimized by adjusting the voltages for excitation of blue
(FITC) and red (PE) channels. Platelet fluorescent intensities were monitored using an
acquisition and analysis application, CellQuestTM (BD Biosciences). A total of 10,000
platelets were analyzed and fluorescent intensities were plotted as a histogram with
statistical values.

Western Blotting and Quantification
Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) [120, 121].

The separated proteins were transferred

electrophoretically [122] to Immobilon-P polyvinylidene fluoride membrane (PVDF,
Milipore, Bedford, MA) with constant voltage (100 V) for 1 hour. Blotted membranes
were then blocked with blocking solution containing 5% nonfat milk in TBS-T (Trisbuffered saline: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20 (Sigma))
containing 0.02% sodium azide (Thermo Fisher Scientific Inc., Waltham, MA) for 1 hour
at room temperature. The blocking solution was replaced with primary antibody diluted
into blocking buffer and membranes were incubated at room temperature for 1-2 hours or
at 4°C overnight. Membranes were washed with TBS-T three times and incubated with
AP-conjugated secondary antibody diluted into blocking buffer for 1 hour at room
temperature. Following three washes with TBS-T, membranes were incubated with
enhanced chemofluorescence (ECF) substrate (GE Healthcare, Piscataway, NJ) for 5
minutes. Membranes were covered with a piece of transparency film (3M, St. Paul, MN)
and substrate fluorescences were detected using TyphoonTM 9400 Phosphoimager (GE
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Healthcare). Quantification of bands was performed using ImageQuant 5.2 software (GE
Healthcare).

Metabolic Labeling of Human Platelets
To metabolically label proteins in human platelets with o-[32P]-phosphoric acid,
PRP from banked human platelets was centrifuged at 900 × g for 10 minutes at room
temperature, followed by resuspension with phosphate-free HEPES-Tyrode’s buffer (20
mM HEPES/KOH, pH 6.5, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 5 mM D-glucose,
12 mM NaHCO3) containing 0.37 units/mL apyrase, 100 ng/mL PGI2, and 1 mM EGTA
in a final platelet concentration of 8 × 108 platelets/mL. The platelet suspension was
labeled with 0.5 mCi/mL o-[32P]-phosphate at 37°C for 1 hour. Labeled platelets were
recovered by centrifugation at 900 × g for 7 minutes and resuspended in an equal volume
of HEPES-Tyrode’s buffer (pH 7.4), the estimated final platelet concentration is
approximately 4 × 108 platelets/mL (50% recovery of resuspension).

Immunoprecipitation of Platelet Proteins
Washed unlabeled or [32P]-labeled platelets (500 µL) were warmed at 37°C for 5
minutes in either a heat block or in the aggregometer, followed by stimulation with the
agonist, thrombin (0.1 U/mL) for 5 minutes. The reaction was stopped by adding equal
volume of 2 × ice-cold IP-lysis buffer (20 mM HEPES/KOH, pH 7.4, 128 mM NaCl, 9
mM MgCl2, 2% Tx-100, 20% glycerol, 2 mM sodium orthovanadate, 2 mM
benzamidine, 2 mM EGTA, 2× EDTA-free protease inhibitor cocktail) and the lysates
were incubated for 30 minutes to 1 hr on ice. The insoluble cytoskeleton was removed
by centrifugation at 13,000 × g for 5 minutes and the supernatant (500 µL) was
precleared with 10 µL Protein A or Protein G-Sepharose beads at 4°C for 30 minutes on
the rotator. The beads were spun down at 500 × g for 10 seconds and the clarified
supernatant was incubated with 5 µg of antibody bound to 10 µL Protein A or Protein GSepharose beads at 4°C for 2 hours on the rotator. Non-specific binding was eliminated
by three washes with 1 mL of 1× ice-cold IP-lysis buffer without protease inhibitor
cocktail at 500 × g for 10 seconds and the bound proteins were eluted with 2× SDS
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sample buffer by boiling for 10 minutes.

Proteins were resolved by SDS-PAGE,

transferred to PVDF membrane, and then analyzed with a specific antibody by western
blotting. For storage phosphor detection of [32P]-labeled proteins, the resolved PVDF
membrane was covered and then exposed to a storage phosphor screen (GE Healthcare)
overnight. The screen was excited at 600 nm and detected the emission intensity peaked
at 390 nm using TyphoonTM 9400 Phosphoimager and analysis of bands was performed
using ImageQuant 5.2 software. For detection of coimmunoprepitates, western blotting
was performed using an antibody for the protein of interest.

Electron Microscopy of Platelets
Washed human or murine platelets were warmed in a 37°C metal block for 5
minutes. Platelets were either kept resting or stimulated with 0.1 U/mL of thrombin for 5
minutes.

The platelets were then processed for electron microscopy as described

previously [42, 46] with slightly modification. An equal volume of 0.1% glutaraldehyde
in White’s saline (120 mM NaCl, 5 mM KCl, 2.3 mM MgSO4, 3.2 mM Ca(NO3), 6.5
mM NaHCO3, 0.42 mM Na2HPO4, 0.19 mM KH2PO4, 0.0005% phenol red) was added to
the platelet suspension for 15 minutes at 37°C. The platelets were centrifuged at 3,000 ×
g for 2 minutes and incubated in ice-cold 3% glutaraldehyde in White’s saline at 4°C for
1 hour. After three washes with White’s saline, the platelets were osmicated in 1% OsO4
in White’s solution. This modification was known to generate a stable fixation of granule
contents and provides a better identification of dense-core granules osmicated platelets
were washed twice with 0.1 M Sorenson’s buffer (16.2 mg/mL KH2PO4, 3.76 mg/mL
Na2HPO4, pH 8.0) and dehydrated in a serial ethanol washes (50%, 70%, 80%, 90%,
100%, and previously unopened absolute ethanol) for 5 minutes. The platelets were
rinsed twice with propylene oxide and infiltrated overnight in a 1:1 mixture of propylene
oxide and Spurr’s resin (10g vinyl cyclohexane dioxide (VCD), 6g DER epoxy resin, 26g
nonenyl succine anhydride (NSA) with final addition of 0.4g dimethylaminoethanol
(DMAE)). After one wash in Spurr’s resin for 1 hour, samples were embedded in 200 µL
Spurr’s resin and polymerized in a 60°C incubator for 48 hours. Polymerized blocks
were sectioned and mounted on copper grids. Following counterstaining with uranyl
acetate, samples were examined using a Philips Tecnai 12 transmission electron
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microscope

(FEI,

Hillsboro,

OR)

and

images

were

obtained

with

Gatan

Digitalmicrograph software (Pleasanton, CA).

Platelet Membrane Fractionation
Platelet membrane fractions were isolated using sonication.

Platelets were

resuspended in sonication buffer (50 mM Tris/HCl, pH 7.4, 250 mM sucrose, 1× protease
inhibitor cocktail) and the concentration was adjusted to 4 × 108/mL.

Resting and

stimulated platelets were placed in an ultrasonic dismembrator Model 100 (Thermo
Fisher Scientific) and disrupted by three rounds of 10 seconds pulses with 50 W output.
The samples were chilled on ice for 10 minutes and the membrane and cytosolic fractions
were separated by ultracentrifugation at 186,000 × g for 1 hour. The membrane fraction
was washed three times with sonication buffer in order to remove cytosol components.
The final membrane pellet (membrane fraction) and cytosol fraction were dissolved in
SDS sample loading buffer. The equivalent amount of platelets for membrane fraction
and cytosol were loaded

Isolation of Platelet Lipid Rafts
Resting and stimulated platelets (1 × 109/mL) were lysed in 2× Raft lysis buffer
(50 mM MES, pH 6.5, 150 mM NaCl, 1% Tx-100, 2× protease inhibitor cocktail), and
mixed with 80% sucrose solution in MES saline (50 mM MES, pH 6.5, 150 mM NaCl).
Final 40% sucrose/platelet lysates (2 mL) were layered into 15 mL ultracentrifuge tubes
(Beckman Coulter), with 30% (6 mL) and 5% (2 mL) sucrose layers added on top.
Samples were centrifuged at 200,000 × g for 18 hours without a break and the tubes were
snap frozen in an ethanol-dry ice chamber for 10 minutes. Nine fractions (1 mL each)
were collected as a frozen entity using a graduated platform for cutting with a hacksaw
(named ‘Raftolator’) and tube debris were removed by centrifugation at 1,000 × g for 2
minutes. Protein concentration was measured in each fraction using BCATM assay and
proteins were concentrated using trichloroacetic acid (TCA) precipitation, followed by
boiling with 2× SDS sample buffer.

Identification of Unknown Proteins by Mass Spectrometry
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Stained specific protein bands were visualized on a UV light box and the gel
image was captured using Molecular Imager Gel Doc XR System and Quantity One 4.6
image analysis software (Bio-Rad). Bands of interest were excised either using the Gel
Doc System or a ProteomeWorksTM automated spot cutter with PDQuest 7.2 software
(Bio-Rad). Digestion with trypsin and peptide analysis by mass spectrometry using
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) method were
performed at the University of Kentucky, Center for Structural Biology Protein Core
Facility (Lexington, KY). Peptide fragments were analyzed for identification of protein
using the web-based search engine MASCOT (Matrix Science Inc., Boston, MA).

Streptolysin-O (SLO) Permeabilized Human Platelet Secretion
This assay was established in the laboratory [123]. Human PRP was obtained
from the Kentucky Blood Center as units (Lexington, KY). Twenty five milliliters of
human PRP were first labeled with 0.4 µCi/mL [3H] 5-HT for 45 min at 37°C. After
centrifugation at 150 × g for 10 min, the supernatant was moved to another conical tube
and centrifuged at 500 × g for 15 min. The pellet was washed twice with Ca2+-free
Tyrode’s Buffer (154 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM D-glucose, 7 mM
NaHCO3, 0.6 mM NaH2PO4, 5 mM sodium PIPES, pH 6.5, 5 mM EGTA, 0.35% BSA)
containing 3 µg/mL apyrase and finally resuspended in Buffer A (120 mM sodium
glutamate, 5 mM potassium glutamate, 20 mM HEPES, pH 7.4, 2.5 mM EGTA, 2.5 mM
EDTA, 3.15 mM MgCl2, 1 mM DTT). The platelet concentration was determined by Z2
Coulter particle counter and size analyzer and adjusted to 5 × 108/mL. Fifty microliters
of platelet suspension were mixed with 50 µL of Buffer A containing 8 mM ATP, 1.6
U/mL SLO (Corgenix, Peterborough, United Kingdom) and the effectors (recombinant
proteins, antibodies, etc.). The reaction was first incubated at RT for 10 min and then 30
min on ice. The samples were then warmed to 25°C using a RT water bath for 5 min and
stimulated with calcium for 5 min. The reaction was stopped by centrifugation at 13,800
× g for 1 min to separate the supernatant from the pellet. The pellet samples were lysed
with 100 µL lysis buffer (PBS, pH 7.4, 1% Triton X-100) for 1 hr on ice. The assay for
secretion from all three granules is similar to the assay used to analyze mice platelet
secretion (see above). The only difference is the usage of an ELISA assay, specific for
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human PF4. This assay was developed in the laboratory by Dr. Todd Schraw and
described in detail in [124].

Cloning of DNAs and Recombinant Protein Production
Proteins Tagged with His6 or GST
The coding region of each protein was amplified by polymerase chain reaction
(PCR) using forward and reverse primers. PCR products and prokaryotic expression
plasmids (pProEX-HTb (Invitrogen, Carlsbad, CA) for His6-tagged protein and pGEXKG for GST-tagged protein) were digested with corresponding endonuclease restriction
enzymes and separated on a 1% low-melting agarose gel (ISC BioExpress, Kaysville,
UT) in TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA). DNA bands were
excised and eluted in sterile water using a Gel Extraction kit (Qiagen, Valencia, CA).
Inserts (PCR products) and vectors (pProEX-HTb or pGEX-KG) were ligated in a 3:1
molar ratio using T4 DNA ligase (Invitrogen) and the ligates were transformed into
DH5α E.coli strain by 45 seconds heat shock at 42°C. Transformed bacteria were
recovered by incubating in 1 mL Luria-Bertani (LB) media at 37°C for 1 hour and grown
on LB/agar plate containing 100 µg/mL ampicillin overnight at 37°C. Each colony was
screened with cloning PCR and double digestion testing with the corresponding enzymes
after purification of plasmid DNA Miniprep kit (Qiagen). The clones were further
confirmed by DNA sequencing at Davis Sequencing (Davis, CA).
For production of recombinant proteins, purified plasmid DNAs were transformed
into the RosettaTM(DE) E coli strain which harbors a plasmid (pRARE) containing rare
tRNA sequences (Novagen, Gibbstown, NJ). The colonies were amplified by culturing
in 100 mL LB media containing 100 µg/mL ampicillin and 35 µg/mL chloroamphenicol
(LB/amp/cam) and the culture was further scaled to 2 L. Recombinant protein production
was induced by adding 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 4 hours at
37°C or overnight at 16°C. The cells were harvested by centrifugation at 6,000 × g for 5
minutes and washed once in ice-cold PBS.

The bacterial pellet was weighed and

resuspended in breaking buffer. The cells were broken by three passages using French
Press cell disruptor at 12,000 psi and centrifuged at 100,000 × g for 1 hour. The
supernatant was filtered using 0.2 µm nylon filter (Fisher Scientific) and applied to
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column purification using either Ni2+-NTA agarose or glutathione agarose. The purified
recombinant proteins were dialyzed in HEPES buffer (20 mM HEPES/KOH, pH 7.4, 100
mM NaCl, 2 mM MgCl2, 1 mM DTT, 5% glycerol) overnight at 4°C and the aliquots
were stored at -80°C.

Syntaxin-Containing Complexes Production
Dual expression plasmids for full-length SNAP-23, Munc18a, and Munc18c,
syntaxin-2 (residues 1-251, representing the cytoplasmic region), and syntaxin-4
(residues 1-265, representing the cytoplasmic region) were constructed using pRSFDuet1.

Amino acid substitutions were introduced using the site-directed mutagenesis

(Strategene).

All syntaxin-containing complexes were overexpressed in the Rosetta

Escherichia coli cells (Novagen) and purified from cell lysates by both Ni2+-affinity
chromatography and S-protein affinity chromatograph.

Production of His6-Tomosyn-1 from Sf9 Cells
His6-tomosyn-1 full length and fragments were generated in Sf9 (Spodoptera
frugiperda) cells according to the manufacturer’s instruction. Full-length tomosyn-1
cDNA was inserted into the pFastBac-HTB and the sequence was confirmed by
commercial dideoxy sequencing.

The pFastBac-HTB-tomosyn-1 plasmid was then

transformed into DH10Bac competent cells (Invitrogen) and tomosyn-1-Bacmid was
purified according to the manufacturer’s instructions.
Tomosyn-1-Bacmid was used to transfect Sf9 cells which had been previously
adapted to serum-free suspension culture (SF-900 II SFM medium, Invitrogen). After
two days, the supernatant of the transfected Sf9 cells was collected (containing secreted
baculovirus, P1 virus) and used to directly infect a new culture of Sf9 cells to produce P2
virus.

P2 virus titer was determined by a virus plaque assay according to the

manufacturer’s instructions. P2 virus was then used to infect 200 mL mid log-phased Sf9
cells (1~2 × 106/mL) at the indicated multiplicity of infection (1 to 5) for 3 days. The
whole cell pellet was collected, washed twice with cold PBS, and resuspended in 20 mL
cold

Lysis

Buffer

(50

mM

Tris,

pH

8.0)

in

the

presence

of

1

mM

phenylmethanesulphonylfluoride (PMSF) and protease inhibitor cocktail (Roche Applied
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Science, Indianapolis, IN). The cell suspension was sonicated 10 times, 30 sec each on
ice. The lysate was first centrifuged at 500 × g for 10 min to remove unbroken cells and
disrupted cell debris, then at 13,800 × g for 20 min at 4°C. The supernatant was loaded
to a 1 mL Ni2+-NTA column pre-equilibrated with 50 mM Tris (pH 8.0). The column
was washed sequentially with 10 volumes of Buffer I (50 mM Tris, 500 mM NaCl, pH
8.0) and of Buffer II (50 mM Tris, 500 mM NaCl, 5 mM imidazole, pH 8.0), then eluted
with 5 mL of Elution Buffer (50 mM Tris, 500 mM NaCl, 0.5 M imidazole, pH 8.0).

Generation of the Tomosyn-1 and Syntaxin-11 Antibodies
DNAs encoding the rat tomosyn-1 and murine syntaxin-11were inserted into the
pProEX-HTB vector and used to transform Rosetta DE3 competent E. coli. The His6tagged insoluble proteins were dissolved in 8 M urea then purified under denaturing
conditions. The eluted proteins were dialyzed extensively with PBS in order to remove
residue imidazole and urea. The protein concentration was analyzed using SDS-PAGE
with BSA as a standard.
To generate antibodies, 1 mg of protein was emulsified in 1 mL Freund’s
complete adjuvant (Sigma) and injected subcutaneously into a total of ten sites along the
back of a New Zealand Rabbit (100 µL/site). Two weeks later, the rabbit was boosted
with 0.25 mg of protein emulsified with Freund’s incomplete adjuvant (Sigma) using a
similar pattern of injection sites. Two weeks following the boost, 35 mL of blood was
collected from the rabbit ear vein. Following the first bleed, the rabbit was boosted then
bled every two weeks for 15 cycles. Sera were prepared, and stored as aliquots at -20°C.
To affinity purify the antibodies, purified protein was coupled to 2 mL GSHAgarose beads. The column was washed with 20 volumes of PBS to remove unbound
protein, then 20 volumes of 200 mM HEPES (pH 8.5). The column was incubated with
10 mL of 20 mM dimethyl pimelimidate (DMP) in 200 mM HEPES (pH 8.5) at RT for 1
hr with gently rocking. After removing the crosslinking solution, 10 mL of 200 mM
ethanolamine (pH 8.2) was added and incubated for 30 min at RT with gently rocking to
terminate any residual crosslinker. After washing the column with 10 volumes of Elution
Buffer (150 mM NaCl, 200 mM Glycine/HCl, pH 2.0), the column was washed with TBS
(25 mM Tris, 150 mM NaCl, pH 7.5). Ten milliliters of sera were diluted, 1:1, with TBS
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and filtered through a 0.2 µm filter. The filtered sera was loaded onto the column and
incubated overnight at 4°C. The column was sequentially washed with 10 volumes of
TBS, 10 volumes of Wash Buffer (500 mM NaCl, 20 mM Tris/pH 7.4, 0.1% Triton X100), and 10 volumes of TBS. The column was eluted with 10 volumes of Elution
Buffer. One milliliter fractions were collected into 1.5 mL microtubes containing 100 µL
the Neutralizing Buffer (2 M Tris, pH 8.5). Antibody was collected, concentrated,
dialyzed against PBS, and stored as aliquots at -20°C. The antibody concentration was
determined by Bicinchoninic acid (BCA) assay (Pierce, Rockford, IL). The affinitypurified anti-tomosyn-1 antibodies immunoprecipitate endogenous tomosyn-1 from
platelet extracts (Figure 2-1).

40

41

Figure 0-1Figure 2-1 Generation of Tomosyn-1 Antibodies

Figure 2-1. Generation of Tomosyn-1 Antibodies.

Tomosyn-1 antibodies were

generated by immunizing rabbit with purified recombinant tomosyn-1 fragments. (A)
Denaturing purified recombinant His-tagged B-fragment and F-fragment of tomosyn-1
were separated on a 10% SDS-PAGE gel and visualized by Commassie Brilliant Blue R250 staining. These two recombinant protein preps were pure as determined by western
blotting for tomosyn-1 monoclonal antibody and mass spectrometry (the lower bands are
fragments of corresponding proteins) and used as antigen for antibody production. Two
fragments of rat tomosyn-1 are indicated as B and F of tomosyn-1. B-fragment was
cloned from N-teriminal sequence (1-390 aa) of rat tomosyn-1, which is predicated to
form the first β-propeller structure, while the F-fragment is from the C-terminal region
(670-1056 aa) and has a flexible predicated structure. (B) Antibodies generated against
both B and F-fragments of tomosyn-1 are able to immunoprecipitate endogenous
tomosyn-1 protein from platelet extracts. (C) Anti-tomosyn-1 polyclonal antibodies also
recognize the endogenous tomosyn-1 protein from resting, PGI2 treated, and thrombin
activated platelet extracts.
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Tail Vein Bleeding Time
Tail vein bleeding time was determined as described by Broze et al. [125].
Briefly, mice 5-6 weeks of age were anesthetized with ketamine 75 mg/kg i.p.

A

transverse incision was made with a scalpel at a position around 3 mm from the tip of
murine tail. Then the tail was immediately immersed into a 15 mL tube filled with 37°C
normal saline. The time from incision to bleeding cessation was recorded as the bleeding
time.

Animals with prolonged bleeding times greater than 10 min were stopped

manually.

FeCl3-Induced Arterial Thrombosis in vivo Model
FeCl3-induced arterial thrombosis is a method to analyze platelet functional
defects in vivo [126, 127]. This model is believed to be one of the better models to mimic
thrombotic disease in vivo because it generates a controlled and localized vascular
damage that the platelets respond to. Mice 8-12 weeks of age were anesthetized with
Avertin (0.2 g/kg, i.p.) in a supine position on a 37°C heating pad. The toe-pinch reflex
was used to monitor the anesthesia state. A segment of the left carotid artery was
exposed using blunt dissection under a dissecting microscope. A miniature Doppler flow
probe (0.5VB, Transonic system Inc., Ithaca, NY, USA) was placed on the carotid artery
to monitor blood flow. Thrombus formation was induced by placing a small piece of
filter paper saturated with 5% FeCl3 solution in saline on the top of the vessel for 3 min
and then removed. Time from application to cessation of flow, defined as flow stopped
for more than 1 min, was measured. Experiments were terminated at 30 min.

Statistics Analysis
All statistical analysis was performed using ANOVA (GraphPad Prism 5). P
values less than 0.05 were considered significant.

Copyright © Shaojing Ye 2012
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Chapter THREE
The Role of Syntaxins in Platelet Secretion

Introduction
It is generally accepted that secretion is mediated by formation of transmembrane SNARE complexes which drive two lipid bilayers to fuse together, leading to
the release of granule contents. The minimal functional SNARE complex is formed by
one v-SNARE and two t-SNAREs.

According to the original SNARE hypothesis,

specificity for different membrane fusion events is provided by specific interaction of tSNARE/v-SNARE pairs [33, 128]. This has been challenged in recent years. A more
modern version of the hypothesis posits that only certain SNARE complex combinations
are fusogenic [30, 79]. In platelets, it has been demonstrated that VAMP-8 is required for
platelet secretion. VAMP-8 is the primary VAMP among the four known platelet
VAMPs (VAMP-2, -3, -7, -8); only VAMP-8 null mouse platelets have a secretion
defect. Since this defect is not complete, unless Tetanus toxin is added, VAMP-2 and -3
must serve some compensatory, secondary role with lower efficacy [46]. It has been
demonstrated that SNAP-23 is required for platelet secretion [40, 41]. The role of the
syntaxins has been more equivocal and has not been determined definitively.
Several syntaxins (-2, -4, -7, -11, and Vti1b) are present in platelets. Of the
known syntaxins in platelets, syntaxin-2 and -4 were the only two that were found on the
plasma membrane [38]. Thus, they were the most likely candidates to mediate exocytosis.
Consistently, introduction of a syntaxin-2 polyclonal antibody into SLO-permeabilized
human platelets inhibited release from α-granules, dense granules, and lysosomes [40,
41]. In vitro studies have also shown that syntaxin-2 can interact with SNAP-23 and
VAMP-8 [129], suggesting that syntaxin-2 can form SNARE complexes. In parallel,
studies of syntaxin-4 suggested that it also played a role in platelet exocytosis.
Introduction of a syntaxin-4 monoclonal antibody into SLO-permeabilized human
platelets inhibited release from α-granules and lysosomes and co-immunoprecipitation
experiments showed that syntaxin-4 could form complexes with VAMP-8 and SNAP-23
[41, 44]. These results were consistent with other studies showing a role for syntaxin-4
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in exocytosis; syntaxin-4 is required for insulin secretion from pancreatic beta-cells [70,
130]. However, there were inconsistencies. A syntaxin-4-specific polyclonal antibody
had no effect on platelet secretion (Lemons et al unpublished) and reduction of the
syntaxin-4 chaperone Munc18c and concomitant reduction in syntaxin-4 had no effect on
release from murine platelets [80]. Given the possibility that the antibodies used may not
be completely isoform-specific or that steric hindrance could account for the inhibitory
effects of the antibodies, we used transgenic mice to reexamine the roles of syntaxin-2
and-4 in murine platelets.
Syntaxin-2 KO mice are viable but the null males are sterile due to abnormal
testicular development and impaired spermatogenesis [119]. Syntaxin-4 is important for
embryo development and its global deletion causes early embryonic lethality before day
7.5 (E7.5). Syntaxin-4 is probably required for glucose transporter 8 transports in
embryoblasts [131]. These knockout mouse systems make ideal tools to re-examine the
roles of syntaxin-2 and -4 in platelet exocytosis because that are not subject to the same
ambiguities as are the permeabilized platelet assays. Surprisingly, in our analysis (this
Chapter), platelets lacking both syntaxin-2 and -4 had no secretion defect, suggesting that
other syntaxins are required for platelet exocytosis.
Considering that syntaxin-7 is not located on the plasma membrane and
introduction of syntaxin-7 antibody into platelets did not affect platelet secretion [42], we
reasoned that that syntaxin-7 may not be critical for platelet secretion. The syntaxin,
Vti1b, was found in platelets by western blotting analysis during my thesis preparation.
Vti1b has been shown to be important in other hematopoietic cells. Vti1b is necessary
for the release of secretory lysosomes in cytotoxic lymphocytes [131, 132]. However no
evidence is available to show that it plays an important role in platelet secretion. Based
on the close sequence homology with prototypical t-SNAREs, the mammalian syntaxin
family can be further divided into Qa (syntaxin-1, -2, -3, -4, -5, -7, -10, -11, -16, etc.), Qb
(Vti1a, Vti1b, etc.), Qc (syntaxin-6, syntaxin-8, etc.).

SNAP-23/25 t-SNAREs are

considered Qb/Qc SNAREs. Since SNAP-23 appears to be required, any candidate
syntaxin in platelet should be a Qa SNARE. Since Vti1b is a Qb t-SNARE it is not likely
to be critical for platelet secretion.
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Among the five known syntaxins in platelets, syntaxin-11, by default, appears to
be the most important candidate for a role in platelet secretion [40, 41, 73]. Most
mammalian syntaxins are type II integral membrane proteins anchored by their Cterminal TMD [74].

Syntaxin-11 is a non-conventional syntaxin without a TMD.

Syntaxin-11 has been shown to be associated with late endosomes and the trans-Golgi
network in Hela cells [37]. Interestingly, syntaxin-11 mutations are associated with
Familial Hemophagocytic Lymphohistiocytosis Type 4 (FHL4).

FHL4 is a rare

autosomal recessive disorder of immune dysregulation associated with uncontrolled T
cell and macrophage activation.

Syntaxin-11 deficient NK-cells exhibit a cytotoxic

granule degranulation defect. Thus it has been thought that syntaxin-11 is involved in
granule-plasma membrane fusion. However, other studies suggest that syntaxin-11 might
be involved in granule-granule fusion instead [75, 76]. Moreover, syntaxin-11 has been
shown to play a negative, regulatory role in macrophages by controlling access to Vti1b
and thus affecting late endosome to lysosome fusion [77]. Although the exact role of
syntaxin-11 in immune cell exocytosis is still not clear, the genetic association of
syntaxin-11 mutations with FHL4 is clear. We took advantage of this in our analysis of
platelets from an FHL4 patient that lacked syntaxin-11.
The goal of the studies described in this Chapter was to determine which syntaxin
is required for platelet secretion. We used syntaxin KO mouse models and syntaxin-11
deficient human platelets. Deletion of syntaxin-2 or -4 alone or in combination had no
effect on secretion from murine platelets. Platelet secretion from patients with FHL4,
which lack syntaxin-11, was severely defective. Thus, syntaxin-11, but not syntaxin-2 or
-4, is critical for platelet exocytosis.

Results:
The Effect on Murine Platelets of Deleting Syntaxin-2:
The syntaxin-2 KO mice were on a C57Bl/6J background. Compared to wild type
littermates, the syntaxin-2 null mice had normal size, body weight, and fur color. The
males were sterile and for unknown reasons most females had some problems with
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delivering; thus, producing syntaxin-2 null mice was difficult. These data are consistent
with syntaxin-2 being important for certain physiological processes.
To investigate the specific role of syntaxin-2 in platelets, first we analyzed the
morphology of platelets from the knockout mice. The number and size of the circulating
platelets were in the same range as wild type (Figure 3-7). The ultrastructure was normal
with similar shape, granules, OCS, and mitochondria (Figure 3-1), compared to the wild
type platelets from littermate controls. There were no overt, morphological differences
between platelets from wild type and syntaxin-2 null animals.
To study the specific role of syntaxin-2 in platelet secretion, we first examined
whether deletion of syntaxin-2 affected the levels of other secretory machinery
components (Figure 3-2).

There was no obvious effect on VAMP-2, VAMP-3, or

VAMP-8. There was no significant effect on other t-SNAREs: syntaxin-4, syntaxin-7,
syntaxin-11, or SNAP-23. We confirmed the deletion of syntaxin-2. The protein level of
syntaxin chaperone proteins, Munc18 (a, b, c), appeared normal when probing with
Munc18a/b and Munc18c polyclonal antibodies.
Because a syntaxin-2 polyclonal antibody inhibited secretion in in vitro
permeabilized platelets, syntaxin-2 was hypothesized to be required for platelet secretion.
If this hypothesis was correct, a secretion defect should be observed when using syntaxin2 KO mouse system. Surprisingly the depletion of syntaxin-2 has no secretion defect
(Figure 3-3) from all three granules (α-granules, dense granules, and lysosomes). For
analysis, we performed dose response and a time course of release experiments using
thrombin as agonist [46, 133]. Intact platelets were first loaded with [3H]-5HT, washed
with HEPES buffer, and then stimulated with increasing concentrations of thrombin for 1
min (Figure 3-3, left panel). The platelets were pelleted by centrifugation, and the
supernatants were assayed for the presence of granule cargo markers: [3H]-5HT from
dense granules, PF4 from alpha granules, and β-hexosaminidase from lysosomes. As
expected, agonist-induced release of dense core and α-granule cargo from wild type
platelets (black square symbols) was greater than the release from lysosomes.
Comparison of platelets from wild type and null mice (red circle symbols) showed that
each responded equally to thrombin and released granular cargo to similar extents. To
assess the efficiency of release, the time course of granule release was analyzed by
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stimulating platelets with 0.05 U/mL thrombin (Figure 3-3, right panel). Thrombin
stimulation initiated dense granule release rapidly and appeared to be complete by 45
seconds. This same response also was seen for α-granule and lysosome release, although
the extent of release was not as great as dense granule. Comparison of release kinetics
between wild type and syntaxin-2 null platelets showed no significant difference in the
time course of their granule release.
Additionally, there was no observable defect in platelet aggregation (Figure 3-11)
for syntaxin-2 null platelets. The washed platelets were used after recalcifying with 1
mM CaCl2. Under these conditions platelets from wild type (black color) and syntaxin-2
KO mice (green color) were responsive to thrombin. The platelets showed an initial,
agonist-induced shape-change response followed by aggregation as indicated by the
increase in light transmission. The kinetics and extent of aggregation to 0.1 U/mL of
thrombin were essentially identical (Figure 3-11). The aggregometer measurements are
consistent with the normal secretion (Figures 3-3). Thus, the absence of this t-SNARE
does not result in any gross defect in platelet function.
Even though the in vitro SLO-permeabilized platelet assay had suggested that
syntaxin-2 is important for platelet secretion, deletion of syntaxin-2 in mouse platelets
had no effect on platelet secretion, suggesting that syntaxin-2 is not absolutely required
for platelet secretion. It is possible that syntaxin-2 is not required for platelet secretion or
other syntaxins are compensating for the secretion function when syntaxin-2 is missing.
In order to exclude the possibility, we used the platelet–specific, syntaxin-4 KO mouse
model.

The Effect on Murine Platelets of Deleting Syntaxin-4:
To study the specific role of syntaxin-4 in platelet secretion we used a plateletspecific knockout mouse model. Mice carrying a floxed version of the syntaxin-4 gene
were mated to a Platelet Factor 4 promoter-driven Cre recombinase expressing transgenic
mouse strain. Using platelets from the progeny of that cross, first we analyzed their
morphology. The number and size of circulating platelets were in the same range as for
wild type platelets (Figure 3-7). The ultrastructure was normal with similar shape,
granules, OCS, and mitochondria (Figure 3-4), compared to the wild type platelets from
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littermates. There was no overt difference between the number of granules per platelets
between wild type and null platelets.
Western blotting analysis was performed to determine whether deletion of
syntaxin-4 affects other secretory components. There were no obvious effects on vSNAREs in platelets; VAMP-2, VAMP-7, and VAMP-8 levels were normal (Figure 3-5).
Similarly there were no significant effects on other t-SNAREs, such as syntaxin-2, -7, 11, or SNAP-23. We confirmed the loss of syntaxin-4. The protein levels of the syntaxin
chaperones, Munc18a and Munc18b, appeared normal while Munc18c levels were
reduced.

This is consistent with the notion that Munc18c is a syntaxin-4-specific

chaperone and the stable complex they form is mutually regulated.
If the assumption is that syntaxin-4 is required for platelet secretion, a secretion
defect should be observed when syntaxin-4 is deleted. Surprisingly the depletion of
syntaxin-4 caused no secretion defect (Figure 3-6) from all three granules (α-granules,
dense granules, and lysosomes). In Figure 3-6 left panel, a thrombin titration experiment
was performed using 1 min as the incubation time. Secretion from each of the three
granules showed the expected dose dependence. Comparison of platelets from wild type
(black square symbols) and null mice (red circle symbols) showed that each responded
equally to thrombin and released granular cargo to similar extents.

To assess the

efficiency of release, the time course of granule release was analyzed. When stimulated
with 0.05 U/mL of thrombin, release from all three granules is clearly observed (Figure
3-6 right panel). Dense granule release was the fastest secretion event, followed by
release from α-granules and lysosomes. Dense granule secretion was observed at 15
seconds when stimulated with 0.05 U/mL of thrombin and completed by 30 sec. αgranule secretion and lysosomal secretion were slightly delayed. They were detectable at
15 sec and completed by 60 second. The extent of secretion also differed among these
three granule secretion events. Over eighty percent of dense granule cargo was released
while ~40% of α-granule cargo and lysosome marker were released when platelets were
stimulated with 0.05 U/mL of thrombin for 1 min. However, in summary, there was no
significant defect in the kinetics or extent of secretion from all three granules in the
syntaxin-4 deficient platelets.
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Additionally, there was no observable defect of platelet aggregation (Figure 3-11)
of syntaxin-4 deficient platelets. Washed platelets were used after recalcification with 1
mM CaCl2. Under these conditions platelets from wild type (black color) and syntaxin-4
KO mice (blue color) were responsive to thrombin. The platelets showed an initial,
agonist-induced shape-change response followed by aggregation as indicated by the
increase in light transmission. The kinetics and extent of aggregation in response to 0.1
U/mL of thrombin were essentially identical (Figure 3-11).

The aggregometer

measurements were consistent with normal secretion (Figures 3-6). Thus, the absence of
this t-SNARE does not result in any gross defect in platelet function.
Even though the in vitro SLO-permeabilized platelet assay has suggested that
syntaxin-2 and -4 are important for platelet secretion, syntaxin-2 and syntaxin-4 single
KO mouse platelets have no secretion defect, arguing that neither syntaxin-2 nor
syntaxin-4 alone is required for platelet secretion. At the time of these experiments, only
three syntaxins (syntaxin-2, -4, -7) were known in mouse platelets and it has been
discussed syntaxin-7 was not felt to be important for platelet secretion [40].

One

possibility is that syntaxin-2 and -4 could be equally and inter-changeably used. To
exclude this possibility, we then generated syntaxin-2/4 double KO platelets by crossing
syntaxin-2-/- mice and syntaxin-4flox/flox/PF4-Cre+ mice. If both syntaxin-2 and -4 are the
primary syntaxins required for platelet secretion, depletion of both should inhibit granule
secretion.

The Effect on Murine Platelets of Deleting both Syntaxin-2 and -4:
To investigate whether syntaxin-2 and -4 together are important for platelet
secretion, we utilized a syntaxin-2/4 double KO murine model. Platelets morphology was
first analyzed.

The size of circulating platelets is normal while the number is

significantly reduced compared to wild type littermate (Figure 3-7). The ultrastructure is
normal (Figure 3-8), compared to platelets from wild type littermates. There was no
significant difference between the number of granules per platelets between wild type and
null platelets. Despite the thrombocytopenia, there was no overt morphological difference
in the double KO platelets.
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To study the specific role of syntaxin-2/4 in platelet secretion, we first analyzed
the levels of known elements of the platelets secretory machinery and found that loss of
both syntaxin had no effect on the v-SNAREs (VAMP-2, -3, -8), other t-SNAREs
(syntaxin-7 and -11), or the syntaxin chaperone proteins, Munc18a and Munc18b. There
was a loss of Munc18s since syntaxin-4 was missing (Figure 3-9). Loss of syntaxin-2/4
also did not affect the expression of several cell surface membrane protein: GPIIb/IIIa,
GP1bβ, PECAM-1, and GPVI (Figure 3-10), suggesting depletion of syntaxin-2/4 in
platelets does not overtly affect membrane protein trafficking.
To determine whether both syntaxin-2 and syntaxin-4 are important for platelet
aggregation, we tested platelets from the syntaxin-2/4 double KO mice. Washed and
recalcified platelets were analyzed for their aggregation activity. Under these conditions
platelets from wild type (black color) and syntaxin-2/4 KO mice (red color) were
responsive to thrombin. The platelets showed an initial, agonist-induced shape-change
response followed by aggregation as indicated by the increase in light transmission. The
kinetics and extent of aggregation to 0.1 U/mL of thrombin showed no significant defect
compared to syntaxin-2 KO, syntaxin-4 KO, and wild type platelets from the
corresponding littermates. (Figure 3-11).
Considering the syntaxin-2 polyclonal antibody and syntaxin-4 monoclonal
antibody could inhibit the in vitro permeabilized platelet secretion, a secretion defect
should be observed when double deletion of syntaxin-2/4 was used, surprisingly the
double depletion of syntaxin-2/4 resulted in no secretion defect (Figure 3-12). As shown
in Figure 3-12 left panel, in a thrombin titration experiment, using 1 min as the
incubation time, secretion from each of the three granules showed the expected dose
dependence. Comparison of platelets from wild type (black square symbols) and null
mice (red circle symbols) showed that each responded about equally to thrombin and
released granular cargo to similar extents. Interestingly, the release from α-granule was
significantly enhanced when both syntaxin-2 and -4 were missing, suggesting that
syntaxin-2 and -4 might compete with the important syntaxin for secretion. To assess the
efficiency of secretion, the time course of granule release was analyzed.

When

stimulated with 0.05 U/mL of thrombin, release from all three granules is clearly
observed (Figure 3-12 right panel). Dense granule release is the fastest, followed by
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release from α-granules and lysosomes. Dense granule secretion was observed at 15
second when stimulated with 0.05 U/mL of thrombin and completed by 30 sec. α Granule secretion and lysosomal secretion are slightly delayed. They were detectable at
15 sec and completed by 60 second. The extent of secretion also differs among these
three granule secretion events. Over eighty percent of dense core granule cargo was
released while ~60% of α-granule cargo and lysosome marker were released when
platelets were stimulated with 0.05 U/mL of thrombin for 1 min. There is no defect in
the kinetics or extent of secretion from all three granules in the syntaxin-2/4 double
deficient platelets, suggesting that neither syntaxin-2 nor -4 are required for platelet
secretion. Compared to the wild type platelets, deletion of both syntaxin-2 and -4 seems
to enhance the secretion from α-granules, indicating the syntaxin-2 and -4 might be
competing with the real functional syntaxin for formation of functional SNARE complex,
thus membrane fusion.

A similar enhancement, though subtle, was noticed when

examining the secretion from VAMP-3 null platelets [53]

Syntaxin-11 is the Most Abundant t-SNARE in Human and Murine Platelets:
From the data above, it is clear that previous analysis of syntaxin function in
permeabilized platelets may be flawed. How previous experiments could have reached
such different conclusions is an open question that we attempt to resolve in this section.
Initial experiments sought to determine the relative levels of the different platelet
SNAREs. As was shown for VAMP-8, and assumed for SNAP-23, the most abundant
SNARE appears to be the most functionally relevant. Additionally, it seems possible that
the antibodies originally used in the permeabilized platelet could have some crossreactivities that were initially undetected (since syntaxin-11 was not know that the time).
The sequence in each mammalian t-SNARE is highly conserved, for example, the
sequence identity for syntaxin-11 is 84.67 % between mouse and human. In terms of
detectable t-SNAREs, a total of five syntaxins (syntaxin-2, -4, -7, -11 and Vti1b) and
SNAP-23 have been identified in platelets (notes: Vti1b was found in platelets during the
preparation of this manuscript, so data presented here do not included Vti1b).

To

characterize antibody specificity and understand the syntaxin usage in mouse and human
platelets, we utilized fluorescence-based, quantitative, western blotting of both human
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and mouse platelet extracts. The antibodies used for syntaxin-2, -4, -7, and -11 and
SNAP-23 recognized both human and mouse platelet syntaxins (Figure 3-14).

To

determine the relative abundance of the five t-SNAREs, recombinant proteins were used
to generate a standard curve for quantification.

The platelet extracts from known

numbers of human and mouse platelets were loaded as indicated (Figure 3-15). The
protein level of syntaxin-11 was the most abundant t-SNAREs in both human and mouse
and a molecule per platelet level (Table 3-1). Syntaxin-11 was ~6 fold more abundant
than syntaxin-4 and 3 fold more abundant than SNAP-23 in human platelets while in
mouse platelets syntaxin-11 was 9 fold higher than other t-SNAREs. Comparing human
and mouse t-SNAREs, syntaxin-2, -7, and -11, there were ~2000 molecules of syntaxin-2
per platelet, twice that for syntaxin-7 and 25 fold that syntaxin-11. However the amount
of human syntaxin-4 and SNAP-23 were much higher than in mouse. The specificity of
each antibody was also assessed by comparing their immuno-reactivities to the various
recombinant syntaxins (Figure 3-16A).

Among the four syntaxin antibodies, the

syntaxin-2 polyclonal antibody, which was generated by our group and used for
previously studies [40, 41], showed some cross reactivity with both syntaxin-4 and
syntaxin-11. However, the small amount of cross reactivity does affect the fact that
syntaxin-11 is the most abundant t-SNARE in both human and mouse platelets. From
these data two points are clear, the originally used anti-syntaxin-2 antibody used in
permeabilized platelets does cross react with syntaxin-11 (also see below) and syntaxin11 is the major syntaxin by mass in platelets. These data would support the hypothesis
that syntaxin-11 is required for platelet secretion.

Syntaxin-11 is Required for Platelet Secretion:
Among the four known syntaxins in platelets, all except syntaxin-11 have been
ruled out as the most important syntaxin required for platelet secretion. Quantification of
t-SNAREs (Table 3-1) in platelets shows that syntaxin-11 is the most abundant t-SNARE
in both human and mouse platelets, suggesting that syntaxin-11 could be the most
important t-SNARE in platelets. The fact that syntaxin-2 deficient platelets have no
secretion defect argues that the inhibition phenotype by the syntaxin-2 polyclonal
antibody [40, 41] may be caused by a steric effect or more likely by cross reactivity.
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Indeed, the original syntaxin-2 polyclonal antibody showed cross reactivity to syntaxin11 (Figure 3-16A). Additionally, the antibody also recognized endogenous syntaxin-11
since syntaxin-11 could be co-immunoprecipitated by the syntaxin-2 antibody (Figure 316B).

The syntaxin-2 antibody cross reactivity not only explains the inconsistency

between permeabilized platelet secretion data and knockout, intact platelet secretion data,
but also suggests a role for syntaxin-11 in platelet secretion. To address this question, we
collaborated with Dr. Alexandra H. Filipovich at Cincinnati Children’s Hospital Medical
Center to study platelets from a FHL4 patient.

The patient, whose platelets were

analyzed, had bleeding problems and a profound defect of NK cell degranulation
(personal communication).

Genetic analysis demonstrated that the patient was

homozygous for 173T>C mutation in the syntaxin-11 gene. This point mutation causes a
reduction in syntaxin-11 protein levels, below the limits of detection. The levels of 15
other secretory machinery components are normal (Figure 3-17A). As perhaps expected
since Munc18b is a potential chaperone for syntaxin-11, Munc18b levels were negatively
affected. The mutation causes a change in D58 to R on the Habc region. It is possible
that this point mutation may disrupt the protein folding and/or stability of syntaxin-11. To
address whether syntaxin-11 is required for platelet secretion, we examined release from
all three granules in both thrombin-titration and time course experiments. A thrombin
titration experiment was performed using 1 min as the incubation time. Secretion from
each of the three granules from normal control platelets and lysosome from FHL4 patient
showed the expected dose-dependence (Figure 3-17B). Secretion from dense granule and
α-granule release was almost abolished in the FHL4 patient’s platelets. To assess the
efficiency of release, the time course of granule release was analyzed. The time course of
[3H]-serotonin from dense granule and PF4 release from α-granule was nearly abolished
in the syntaxin-11 deficient platelets from the FHL4 patient (Figure 3-17C). Release of
β-hexosaminidase from lysosomes was only modestly decreased, suggesting that
syntaxin-11 is essential for dense and α-granule release while lysosome release is not
fully dependent on syntaxin-11.

Platelet Aggregation, ATP Release, and P-selectin Exposure are Defective in
Syntaxin-11 Deficient Platelets from a FHL4 Patient:

54

To confirm that syntaxin-11 is required for platelet exocytosis, we further
analyzed syntaxin-11 null platelets from the same FHL4 patient. Figure 3-18A, i-iii
shows that the aggregation of washed platelets (control, black traces; patient, gray traces)
stimulated with 0.1 U/mL thrombin, 10 µg/mL collagen, or 100 µM A23187, was
significantly defective for the syntaxin-11 deficient platelets.

Concomitantly, ATP

release, as measured with luciferin/luciferase luminescence, from dense granules was
totally abolished (Figure 4A, iv-vi).

Secretion-dependent aggregation was defective

when stimulated with thrombin or A23187 (Figure 3-18A, i and iii) by comparison with
collagen induced aggregation (Figure 3-18A, ii) since collagen induced aggregation is
less dependent on secondary wave of ADP release [134]. A23187 is an ionphore, which
increases intracellular calcium and circumvents the need for signaling cascade activation
[117, 118].

Secretion in the presence of A23187 is impaired, suggesting that the

secretion defect seen on syntaxin-11 deficient platelets is not in a signaling step but is
indeed at the fusion step required for secretion (see EM analysis discussion).
To further confirm the secretion defect in the syntaxin-11 deficient platelets, we
also performed flow cytometry analysis. P-selectin is an integral membrane protein in αgranules and its exposure at the platelet surface is widely used as a metric for α-granule
exocytosis.

Compared to normal control and resting platelets, the geometric mean

fluorescence intensity (GMFI) of staining for P-selectin on syntaxin-11 deficient platelets
only slightly increased upon stimulation with 0.1 U/mL thrombin (Figure 3-18B). When
quantified, the P-selectin staining on FHL4 patient’s platelets was 10 fold less than that
of control, suggesting that α-granule secretion, as measured by P-selection exposure, is
almost abolished.
To exclude the possibility that the observed secretion defects could be caused by a
defect in granule biogenesis or platelet activation, we examined platelet cargo levels and
other parameters of platelet activation. The level of PF4, an α-granule-specific cargo
protein, was similar to wild type (Figure 3-17A). Based on the secretion experiments
discussed about, the platelet levels of β-hexosaminidase and PF4 were similar: for PF4
from α-granules, there were ~2331 ± 184 pg/2.5×108 control platelets and 2220 ± 86
pg/2.5×108 in the syntaxin-11 deficient patient platelets; for β-hexosaminidase there were
~37 ± 5 U/2.5×108 control platelets (n=24) and 30 ± 5 U/2.5×108 in the syntaxin-11
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deficient patient platelets. We also examined two important platelet activation bench
marks: platelet cytoskeletal reorganization and integrin αIIbβ3 activation. A hallmark of
platelet activation is integrin αIIbβ3 activation [116-118]. The activated αIIbβ3 can be
measured with the conformation-specific, PAC-1 antibody. Flow cytometry analysis was
performed. The traces of PAC-1 labeling in thrombin activated platelets (grey trace)
from control and FHL4 patient shift to the right, suggesting that both platelet preparations
are activated upon thrombin stimulation (Figure 3-18C). Compared with the control, the
mean fluorescence intensity (GMFI) of staining for activated αIIbβ3 of syntaxin-11
deficient platelets from FHL4 patient was slightly decreased but not significantly,
suggesting that loss of ADP release might contribute to affect integrin activation. From
these data it appears that syntaxin-11 depletion does not significantly impair platelet
αIIbβ3 inside-out signaling.
Activated platelets undergo dramatic cytoskeletal rearrangement, forming
filopodia and laminipodia and causing granule centralization, which is necessary for
platelet exocytosis [135]. If syntaxin-11 deletion only affects the final fusion step, we
would expect that syntaxin-11 deficient platelets would form filopodia and centralize
their granules, but the granule membrane would not fuse with the plasma membrane
because the relevant SNARE is not present. The expected phenotype would be similar to
that of VAMP-8 null [46] or Munc13-4 null mouse platelets: visible granules centralized
and surround by an actin cytoskeleton [48]. Resting and thrombin-activated platelets
from a control donor and the FHL4 patient were examined by transmission electron
microscopy. As shown in Figure 3-18D, i and ii, resting controls and resting FHL4
platelets have normal shapes with similar arrays of granules, mitochondria, microtubular
networks, and OCS. When stimulated with thrombin (0.1 U/mL; 5 min), both platelets
showed a similar irregular appearance with protruding filopodia. This is consistent with
thrombin-induced cytoskeletal rearrangements (Figure 3-18D, iii and iv).

Control

platelets showed granules depletion while patient platelets showed centralization of the
granules. The presence of granules in the middle of the cells suggests that their fusion
with plasma membrane did not occur. This is consistent with a lack of secretion seen
previously [48] and also indicates that the thrombin induced signaling required for
cytoskeletal rearrangements is still intact in the syntaxin-11 deficient platelets.
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Syntaxin-11 Has Forms SNARE Complexes with SNAP-23 and VAMP-8:
It is clear that VAMP-8 is the primary v-SNARE required for platelet secretion
and SNAP-23 is one of two t-SNAREs to form the core SNARE complex in platelets. If
syntaxin-11 is the primary t-SNARE required for platelet secretion, syntaxin-11 should
be present in SNARE complexes with SNAP-23 and VAMP-8. Studies by Valdez at al.
[37] have demonstrated that syntaxin-11 is capable of binding to VAMP-2 and SNAP-23
in vitro and SNAP-23 in lymphocytes in vivo. To address this question in platelets,
experiments were designed to determine if endogenous syntaxin-11 associates with
endogenous SNAP-23 in platelets in vivo. Both resting and thrombin-activated human
platelets were lysed with Triton X-100-containing buffer and immunoprecipitations were
performed using control IgG and anti-syntaxin-11 polyclonal antibody. Western blotting
using a syntaxin-11-specific antibody confirmed that syntaxin-11 was present in both the
anti syntaxin-11 (Figure 3-19A) and the anti-SNAP-23 immunoprecipitates [Karim et al
in preparation].

This demonstrates that syntaxin-11 is associated with SNAP-23 in

platelets. Moreover, syntaxin-11 co-immunoprecipitated with VAMP-8 in both resting
and thrombin-activated platelet extracts (Figure 3-19, panel A). Syntaxin-11 is also
associated with VAMP-3 in resting platelets but not in activated platelets. There was no
association between syntaxin-11 and syntaxin-4, further confirming that the syntaxin-11
antibody is specific (Figure 3-16).

The observation that syntaxin-11 co-

immunoprecipitated with syntaxin-2 from both resting and activated platelets may be
caused by the cross-reactivity of syntaxin-2 antibody used for the western blotting.
However, it is possible that syntaxin-2 was present in a different complex considering
syntaxin-2 can form complex with SNAP-23 and VAMP-8. Taken together, syntaxin-11
is associated with both core SNARE complex components: SNAP-23 and VAMP-8 in
activated platelets, demonstrating syntaxin-11 can form SNARE complexes with SNAP23 and VAMP-8 in vivo.

Discussion:
It is generally believed that any regulated biological exocytosis is a SNARE–
mediated, membrane fusion process. We hypothesized that there is a syntaxin required
for platelet secretion. The potential candidates were syntaxin-2 and -4 considering they
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are important for permeabilized platelet exocytosis [40, 41, 44]. The fact that syntaxin2/4 double deletion murine platelets had no secretion defect suggests that syntaxin-2 and
-4 are not the absolutely required for platelet secretion. But mild secretion enhancement
from α-granules and lysosomes (Figure 3-12) argues that syntaxin-2/4 may be involved
somehow.

The similar observation was found with the VAMPs.

A secretion

enhancement in VAMP-3 KO mice platelets was observed [46]. Perhaps syntaxin-2/4
may have the similar role to VAMP-3: serving as secondary t-SNARE.

Further

experiments will we required to make this assessment. However, it should be noted that
the defect in secretion in the syntaxin-11 deficient platelets was more severe than that in
the VAMP-8 null platelets. This may imply that there are no secondary syntaxins in
platelets.
Data presented in this Chapter demonstrated a required role for syntaxin-11 in
platelet secretion. Depletion of syntaxin-11 in platelets from a FHL4 patient almost
totally abolished dense granules and α-granules secretion (Figure 3-17 and Figure 3-18B)
and severely impaired lysosome secretion (Figure 3-17B). Loss of syntaxin-11 did not
affect granule biogenesis (Figure 3-17), other SNARE proteins (Figure 3-17A) or platelet
activation (Figure 3-18C, 4D) indicating that the secretion defect is due a deficit in the
final fusion step due to a loss of syntaxin-11. Washed platelets from the syntaxin-11
deficient patient also displayed a profound aggregation defect in response to stimulation
with thrombin and A23187 while showing mild defect upon collagen stimulation,
suggesting the secretion-dependent aggregation is ablated since full aggregation requires
the secondary agonists (such as ADP from dense granule) additional stimulation and
more binding surface (such as fibrinogen from α-granules). Moreover, syntaxin-11 forms
SNARE complex with SNAP-23 and VAMP-8 [37]. In summary, these data support the
conclusion that syntaxin-11, but not syntaxin-2 and -4, is the most important t-SNARE
required for platelet secretion and thus for hemostasis.
Syntaxin-2 and -4 may not be required for granule biogenesis, based on the
platelets levels of β-hexosaminidase and PF4, which were similar between wild type and
syntaxin-2/4 KO mice (Figure 3-12). Similarly, the level of cell surface integrin αIIbβ3,
PECAM, GP1bβ, and GPVI (Figure 3-10) from resting platelets were similar, suggesting
that syntaxin-2/4 may not be required for membrane protein transport through ordinary
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secretory pathway. However, whether syntaxin-2 and -4 are important for endocytosis in
platelets is not clear and will required further analysis. A preliminary experiment showed
that platelets from syntaxin-2/4 double KO mice displayed a fibrinogen uptake defect by
western blotting analysis of the total platelet extracts (Figure 3-13), suggesting that
syntaxin-2/4 may be involved in the granule biogenesis through the endocytic pathway.
Western blotting and flow cytometry analysis of other uptake molecules, such as VEGF
and albumin, using syntaxin-2/4 double KO mice will be a good way to explore this point
further.
Syntaxin-2/4 may be important for platelet biogenesis. Compared to normal wild
type and single syntaxin-2 or -4 KO, the syntaxin-2/4 double KO mice have lower
circulating platelet numbers; however, the size and general morphology of platelets was
unchanged. Analysis of megakaryocytes from these mice might yield interesting results.
In sum, syntaxin-2 and -4 are not the most important syntaxins required for platelet
secretion, but they might be important for other platelet functions or for biogenesis.
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Table 1Table 3-1. t-SNAREs in Human and Murine Platelets

Table 3-1. t-SNAREs in Human and Murine Platelets
t-SNAREs

Molecules/Platelet*
Human (n=4)

Murine (n=4)

Syntaxin-2

1,579 ± 429

1,766 ± 121

Syntaxin-4

9,633 ± 75

1,625 ± 184

Syntaxin-7

3,861 ± 564

3,707 ± 372

Syntaxin-11

51,717 ± 5459

46,966 ± 5516

SNAP-23

19,374 ± 5384

5,363 ± 798

*Number of molecules per platelet was calculated using the molecular weight for
Syntaxin-2 (33 kDa), Syntaxin-4 (34 kDa), Syntaxin-7 (30 kDa), Syntaxin-11 (33 kDa),
SNAP-23 (23 kDa).
Certain amounts of human or murine platelet extracts were subjected to western blotting
with the four different syntaxin antibodies and SNAP-23 antibody. Recombinant human
syntaxin-2, -4, -7, or -11 were used to generate a corresponding standard curve for
quantification of the four known syntaxins and SNAP-23.
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Figure 0-1Figure 3-1 Deletion of Syntaxin-2 Does not Affect Resting Platelet Ultrastructure.

Figure 3-1. Deletion of Syntaxin-2 Does not Affect Resting Platelet Ultrastructure.
Washed platelets (4 × 108/mL) from wild type (Wt) and syntaxin-2 platelet specific KO
mice (Stx2 KO) were kept resting by adding PGI2. The platelets were fixed in 0.1%
glutaraldehyde for 15 min at 37°C and 3% glutaraldehyde for 1 hour at 4°C. After
osmication, the fixed platelets were dehydrated then polymerized in Spurr’s resin. The
thin sections of platelets were counterstained with uranyl acetate and the samples were
analyzed using transmission electron microscope. The images were obtained using Gatan
software and only the brightness and contrast were adjusted in Photoshop (the scale bar is
indicated in left panel).
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Figure 0-2Figure 3-2 Deletion of Syntaxin-2 Does not Affect Secretory Machinery Proteins.

Figure 3-2. Deletion of Syntaxin-2 Does not Affect Secretory Machinery Proteins.
Platelet extracts (5 × 107 platelets/lane) from wild type and syntaxin-2 KO (Stx2 KO)
were probed by western blotting with the indicated antibodies.
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Figure 0-3Figure 3-3 Deletion of Syntaxin-2 Does not Affect Platelet Secretion

Figure 3-3. Deletion of Syntaxin-2 Does not Affect Platelet Secretion. Platelets from
syntaxin-2 KO mice (red circle symbols) and wild type control (black quare symbols)
were prepared as described in “Materials and methods”. Aliquots of intact washed
platelets (2.5 × 108 /mL) were incubated with 0.7 mM CaCl2 at RT for 5 min and then
incubated with the indicated thrombin concentration at RT for 1 mins (left panel) or 0.05
U/mL thrombin for the indicated time points (right panel). Release of [3H]-5HT from
dense granules, PF4 from α-granules, and β-hexosaminidase from lysosomes was
measured, and percent secretion was calculated. The points represent the average of
triplicate measurements and the standard deviations are indicated.
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Figure 0-4Figure 3-4 Deletion of Syntaxin-4 Does not Affect Resting Platelet Ultrastructure

Figure 3-4. Deletion of Syntaxin-4 Does not Affect Resting Platelet Ultrastructure.
Washed platelets (4 × 108/mL) from wild type (Wt) and syntaxin-4 platelet specific KO
mice (Stx4 KO) were kept resting by adding PGI2. The platelets were fixed in 0.1%
glutaraldehyde for 15 min at 37°C and 3% glutaraldehyde for 1 hour at 4°C. After
osmication, the fixed platelets were dehydrated then polymerized in Spurr’s resin. The
thin sections of platelets were counterstained with uranyl acetate and the samples were
analyzed using transmission electron microscope. The images were obtained using Gatan
software and only the brightness and contrast were adjusted in Photoshop (the scale bar is
indicated in left panel).
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Figure 0-5Figure 3-5 Deletion of Syntaxin-4 Does not Affect Other SNARE Proteins

Figure 3-5. Deletion of Syntaxin-4 Does not Affect Other SNARE Proteins. Platelet
extracts (5 × 107 platelets/lane) from wild type and syntaxin-4 platelet specific knockout
(Stx4 KO) were probed by western blotting with the indicated antibodies.
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Figure 0-6Figure 3-6 Deletion of Syntaxin-4 Does not Inhibit Platelet Secretion

Figure 3-6. Deletion of Syntaxin-4 Does not Inhibit Platelet Secretion. Platelets from
syntaxin-4 KO mice (red circle symbols) and wild type control (black square symbols)
were prepared as described in “Materials and methods”. Aliquots of intact washed
platelets (2.5 × 108 /mL) were incubated with 0.7 mM CaCl2 at RT for 5 min and then
incubated with the indicated thrombin concentration at RT for 1 min (left panel) or 0.05
U/mL thrombin for the indicated time points (right panel). Release of [3H]-5HT from
dense granules, PF4 from α-granules, and β-hexosaminidase from lysosomes was
measured, and percent secretion was calculated. The points represent the average of
triplicate measurements and the standard deviations were indicated.
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Figure 0-7Figure 3-7 Syntaxin-2/4 Double Deficient Mice Have Lower Circulating Platelets

Figure 3-7. Syntaxin-2/4 Double Deficient Mice Have Lower Circulating Platelets.
Whole blood from syntaxin-2 (n=9), syntaxin-4 (n=8), syntaxin-2/4 double KO mice
(n=28) or wild type littermate (n=20) was collected.
erythrocytes were counted with Hemvet.
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The number of platelets and

Figure 0-8Figure 3-8 Syntaxin-2/4 Double Deficient Mice Have Reduced Circulating Platelets

Figure 3-8. Syntaxin-2/4 Double Deficient Mice Have Normal Ultrastructure.
Washed platelets (4 × 108/mL) from syntaxin-2/4 double KO mice and wild type litter
mate were kept resting by adding PGI2. The platelets were fixed in 0.1% glutaraldehyde
for 15 min at 37°C and 3% glutaraldehyde for 1 hour at 4°C. After osmication, the fixed
platelets were dehydrated then polymerized in Spurr’s resin.

The thin sections of

platelets were counterstained with uranyl acetate and the samples were analyzed using
transmission electron microscope. The images were obtained using Gatan software and
only the brightness and contrast were adjusted in Photoshop (the scale bar is indicated in
left panel).
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Figure 0-9Figure 3-9 Double Deletion of Syntaxin-2/4 Does not Affect Other SNARE Proteins

Figure 3-9. Double Deletion of Syntaxin-2/4 Does not Affect Other SNARE Proteins.
Platelet extracts (5 × 107 platelets/lane) from wild type and syntaxin-2/4 double KO
(Stx2/4 KO) were probed by western blotting with the indicated antibodies.
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Figure 0-10Figure 3-10 Depletion of Syntaxin-2/4 Mice Platelets Has No Effect on Surface Membrane
Expression

Figure 3-10. Depletion of Syntaxin-2/4 Mice Platelets Has No Effect on Surface
Membrane Expression. Washed platelets (1 × 108 platelets/mL) from wild type (Wt),
syntaxin-2/4 double KO (Stx2/4 KO), syntaxin-2 KO (Stx2 KO), and syntaxin-4 KO
(Stx4 KO) were stimulated with or without 0.1 U/mL thrombin for 1 min and then
incubated with FITC-conjugated anti-GPIIb/IIIa, GP1bβ, PECAM-1, and GPVI
antibodies for 15 min at RT. The reactions were stopped by adding 10 volumes of 1%
formaldehyde for 30 min and the fluorescent intensities were measured by flow
cytometry.
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Figure 0-11Figure 3-11 Syntaxin-2/4 Double Deficient Platelets Have Normal Aggregation Function

Figure 3-11. Syntaxin-2/4 Double Deficient Platelets Have Normal Aggregation
Function. Platelets from wild type control (Wt, in black), syntaxin-2/4 double KO
(Stx2/4 KO, in red) mice, syntaxin-2 KO (Stx2 KO, in green) mice, syntaxin-4 KO (Stx4
KO, in blue) mice, were prepared as described in Chapter 2. Platelets were stimulated
with 0.1 U/mL of thrombin and aggregation was measured in the aggregometer.
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Figure 0-12Figure 3-12 Double Deletion of Syntaxin-2/4 Does not Inhibit Platelet Secretion

Figure 3-12. Double Deletion of Syntaxin-2/4 Does not Inhibit Platelet Secretion
Platelets from syntaxin-2/4 double KO (Stx2/4 DKO) mice (red circle symbols) and wild
type control (black square symbols) were prepared as described in “Materials and
methods”. Aliquots of intact washed platelets (2.5 × 108 /mL) were incubated with 0.7
mM CaCl2 at RT for 5 min and then incubated with the indicated thrombin concentration
at RT for 1 min (left panel) or 0.05 U/mL thrombin for the indicated time points (right
panel).

Release of [3H]-5HT from dense granules, PF4 from α-granules, and β-

hexosaminidase from lysosomes was measured, and percent secretion was calculated.
The points represent the average of triplicate measurements and the standard deviation is
indicated.
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Figure 0-13Figure 3-13 Double Deletion of Syntaxin-2/4 Affect Platelet Fibrinogen Storage

Figure 3-13. Double Deletion of Syntaxin-2 /4 Affects Platelet Fibrinogen Storage.
Platelet extracts (5 × 107 platelets/lane) from wild type (Wt), syntaxin-2/4 double KO
(Stx2/4 KO), syntaxin-2 KO (Stx2 KO), and syntaxin-4 KO (Stx4 KO) were probed by
western blotting with anti-fibrinogen antibody. The red arrow indicates the position of
the alpha chain of fibrinogen.
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Figure 0-144 Figure 3-14: Anti-Human Syntaxin Antibodies Recognizes Both Human and Murine Platelet
Syntaxins

Figure 3-14. Anti-Human Syntaxin Antibodies Recognize Both Human and Murine
Platelet Syntaxins. Equal amounts of human or murine platelet extracts (equivalent to
5.0 × 107 platelets/lane) were subjected to western blotting with the indicated antibodies.
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Figure 0-15Figure 3-15: Syntaxin-11 is the Most Abundant t-SNARE in Platelets

Figure 3-15. Syntaxin-11 is the Most Abundant t-SNARE in Platelets. Recombinant
his-tagged human syntaxin-2, -4, -7, -11, and SNAP-23 and GST-tagged murine
syntaxin-11 were used to generate a standard curve for quantification (using Enhanced
Chemi-Fluorescence western blotting) of each t-SANREs in the indicated number of
murine platelets (m) and human platelets (h).
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Figure 0-16Figure 3-16: Endogenous Syntaxin-11 is Recognized by Syntaxin-2 Polyclonal Antibody

Figure 3-16. Endogenous Syntaxin-11 is Recognized by Syntaxin-2 Polyclonal
Antibody. A) Recombinant his-tagged cytosolic domain of human syntaxin-2 (rStx2,
lane 1-3), human syntaxin-4 (rStx4, lane 4-6), human syntaxin-7 (rStx7, lane 7-9), and
GST-tagged human syntaxin-11 (rStx11, lane 10-12) were loaded with a series of
amount: 20 ng, 10 ng, 2.5 ng per lane and probed by western blotting with the indicated
antibodies. B) Human platelet extract was incubated with syntaxin-2 conjugated agarose
beads. The specific bound proteins were eluted and subjected to western blotting by
using indicated syntaxin-11 antibody. Controls include with or without IgG conjugated
agarose beads.
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Figure 0-17Figure 3-17: Syntaxin-11 Deficient Human Platelets Have Secretion Defects

Figure 3-17. Syntaxin-11 Deficient Human Platelets Have Secretion Defects. Platelet
extracts (5.0 × 107 platelets/lane) from control and FHL4 patients were probed by western
blotting with the indicated antibodies (A). [3H]-5HT labeled and washed platelets from
FHL4 patient (red circle symbols) and normal control (black square symbols) were
prepared as described in “Materials and methods”. Aliquots of intact platelets (2.5 × 108
/mL) were incubated with 0.7 mM CaCl2 at RT for 5 min and then incubated with the
indicated thrombin concentration at RT for 1 min (B) or 0.05 U/mL thrombin for the
indicated time points (C). Release of [3H]-5HT from dense granules, PF4 from αgranules, and β-hexosaminidase from lysosomes was measured, and percent secretion
was calculated. The points represent the average of triplicate measurements and the
standard deviation is indicated. The statistical analysis was performed using ANOVA
(GraphPad Prism 5), p values as indicated.

82

83

Figure 0-18Figure 3-18: Depletion of Syntaxin-11 in FHL4 Patient Affects Aggregation

Figure 3-18. Loss of Syntaxin-11 in Platelets Affects Aggregation, ATP Release, and
P-selectin Exposure. A) The washed platelets from control (black traces) and patient
(gray traces) were stimulated with thrombin (0.1 U/mL, i), collagen (10 µg/mL, ii), and
A23187 (100 nM, iii) for 2-3 min. The aggregation traces were monitored in the platelets
(i-iii) concurrently the released ATP monitored by a luciferin/luciferase-induced
luminescence (iv-vi). (B) and (C) Washed platelets (1 × 108/mL) from normal control
(Control) and FHL4 patient (Patient) were stimulated with or without 0.1 U/mL thrombin
for 1 min and then incubated with FITC-conjugated anti-P-selectin, or FITC-conjugated
PAC-1 antibodies for 15 min at RT. The reactions were stopped by adding 10 volumes
of 1% formaldehyde for 30 min and the fluorescent intensities were measured by flow
cytometry. The data from each FACS run were plotted in histogram and graphed using
Geo Mean Fluorescence Intensity (GMFI): P-selectin (B) and PAC-1 (C). D) Deficiency
of syntaxin-11 does not affect resting platelet ultrastructure and cytoskeletonal
rearrangement. Washed platelets (4 × 108/mL) were kept resting by adding PGI2 (i-ii) or
stimulated with 0.1 U/mL thrombin (iii-iv) for 5 min. The platelets were fixed in 0.1%
glutaraldehyde for 15 mins at 37°C and 3% glutaraldehyde for 1 hour at 4°C. After
osmication, the fixed platelets were dehydrated then polymerized in Spurr’s resin. The
thin sections of platelets were counterstained with uranyl acetate and the samples were
analyzed using transmission electron microscope. The images were obtained using Gatan
software and only the brightness and contrast were adjusted in Photoshop.
magnification of images was shown as indicated scale bars.
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The

Figure 0-19Figure 3-19: Syntaxin-11 is Associated with Platelet Core SNAREs

Figure 3-19. Syntaxin-11 is Associated with Platelet Core SNAREs. Platelet extracts
from resting (R) or thrombin stimulated platelets (S) were prepared by solubilization with
1% Triton-100. After clarification, platelet extracts were incubated with syntaxin-11
polyclonal antibody or IgG control for 3 h at 4°C, then extension of 1h by adding ProteinA-Agarose. The bound proteins were eluted and separated by SDS-PAGE, followed by
western blotting with the indicated antibodies.
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Chapter FOUR
The Role of Tomosyn in Platelet Secretion

Introduction
Platelet secretion is critical for hemostasis and thrombosis. Hypoactive platelets
cause bleeding problems while hyperactive platelets cause thrombosis, which eventually
leads to heart attack or stroke. Control and regulation of platelet secretion is very
important for normal platelet function. It has been generally believed that most regulated
exocytosis processes are mediated by highly conserved SNARE proteins. VAMPs (vSNARE), interact with two types of target membrane SNAREs: syntaxin-type and
SNAP-25-type (t-SNAREs), serving as the minimal components to drive bilayer fusion
[33]. An interaction between the v-SNARE and t-SNAREs is been thought to provide the
specificity for individual fusion events, with additional accessory proteins regulating
spatial and temporal aspects of the process [136, 137]. In platelets, the core SNARE
machinery, which includes VAMP-8, SNAP-23, and syntaxin-11, are defined using
genetic and biochemical analysis [40, 41, 46] and [Chapter 3]. Further efforts to look for
t-SNARE interacting proteins are thought to be a method to identify regulatory
components that control SNARE complex formation. These data will build a detailed
picture of SNARE machinery necessary for platelet secretion.

By using t-SNARE

containing complexes as “bait”, we found that tomosyn-1, granuphilin, and Munc18b,
from platelet extracts, could specifically associate with different set of SNARE
complexes. Tomosyn-1 had not been previously identified in platelets. Tomosyn-1,
originally identified as a neuronal, syntaxin1A-binding protein, is a 130 kDa, cytoplasmic
protein. There are two genes for tomosyn (-1 and -2) in mammals. Tomosyn-1 contains
two domains: an N-terminal WD40 repeats and an R-SNARE coiled-coil domain in Cterminus, which are linked by a hypervariable region. The WD40 repeat domain is
predicted to fold into a two, β-propeller structure, which is important for protein-protein
interactions. Tomosyn-1 has three splice variants and shares 98% sequence identity
between human and rat (shown on Fig.1). Over-expression of tomosyn-1 in neuronal or
endocrine cells inhibits secretion, this together with its C-terminal, R-SNARE motif
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suggests that tomosyn-1 plays a negative role in secretion. Consistently, knockdown of
tomosyn-1 in β-cells increases insulin secretion [112]. Also, the loss of tomosyn-1 in
neurons enhances neurotransmitter release [107]. Depletion of tomosyn-1 in C. elegans
causes an increase in neurotransmitter release by enhancing vesicle priming [138, 139].
Although data supports a negative role for tomosyn-1 in exocytosis, there are several
conflicting results from the neuronal field. Tomosyn-1 knockdown in SCG neurons has
been shown to inhibit synaptic transmission [111]. Tomosyn-2 shares the same structure
and alterative splicing pattern with tomosyn-1 and has been thought to have the similar
function as tomosyn-1 [102, 103, 140]. Although data supports a negative role for
tomosyn-1 in exocytosis, there are several conflicting results from the neuronal field.
Tomosyn-1 knockdown in SCG neurons has been shown to inhibit synaptic transmission
[111].
The goal in this Chapter was to identify SNARE regulators and characterize their
function. To this end, we have identified tomosyn-1 in platelets and determined its novel
function in platelets and hemostasis.

Our findings suggest tomosyn-1 is a positive

regulator for platelet secretion, thus important for hemostasis and thrombosis.

Results:
Tomosyn-1 is Present and Associated with SNAREs in Platelets
Although the core SNARE machinery has been studied in platelets, SNARE
complex regulation and its coupling to signaling cascades in the platelet has not been as
well studied.

Among the core SNARE complex components (VAMP, syntaxin, and

SNAP-23), only syntaxin contains a potential regulatory domain (Habc domain),
suggesting syntaxin might be important for regulation of t-SNARE activation and/or
SNARE complex formation. Thus, it seems logical that components which specifically
interact with syntaxins may be potential regulatory proteins.

To identify potential

regulatory proteins from platelet extracts, we performed pulldown assays using syntaxincontaining complexes as “bait” and then analyzed the bound proteins by mass
spectrometry. Four specific bands were resolved by SDS-PAGE and SYPRO Ruby
staining (Figure 4-1A). Mass spectrometry identified all four (labeled as T1, T2, T3, T4)
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(Table 4-1). Tomosyn-1 (T1 and T2) was found to associate with both syntaxin-2/SNAP23 and syntaxin-4/SNAP-23 complexes, which is in agreement with the previous data
that tomosyn-1 can form high affinity ternary complexes with syntaxin4/SNAP-23 [113].
To verify expression of tomosyn-1 in platelets, we probed the platelet lysate (Input) and
pulldown samples with antibodies directed against a peptide sequence in tomosyn-1 (a
region shared by all three isoforms). A specific, immunoreactive band was only seen
when t-SNARE heterodimers were used as “bait” (Figure 4-1B), but not Munc18a and
Munc18c containing complexes were used. This indicates that tomosyn-1 might not coexist with Munc18a or Munc18c on SNARE complexes (Figure 4-1B), but tomosyn-1
could be present in the same complex with Munc18b (Figure 4-1A, -1B). To further
determine which tomosyn-1 isoform is present in platelets. RT-PCR was performed
using b-, m-, and s-tomosyn-1 specific primers. Only m-tomosyn-1 was detected (Figure
4-1C), suggesting m-tomosyn-1 is most abundant isoform in platelets.
Granuphilin, specifically interacted with Munc18a/syntaxin-2 complex, Munc134 and Munc13-1 also specifically bound to this complex but not to the
Munc18c/syntaxin-2 complex suggesting that Munc18a, but not Munc18c, can interact
with Munc13-4 and granuphilin in platelets (Figure 4-8). VAMP-8 and SNAP-23 were
not shown to be present in Munc18a/syntaxin-2 complex. This work was begun before
syntaxin-11’s role was appreciated. Future studies on interacting proteins with syntaxin11 containing complexes will be a fruitful direction to pursue to identify other regulatory
proteins.
M-tomosyn-1 and Munc18a binding to syntaxin-1 has been shown mutually
exclusive using recombinant proteins [104]. We found that tomosyn-1 and Munc18b
were associated with SNAP-23/syntaxin-2 complex (Figure 4-1A, -1B). Our finding is
consistent with studies from adipocytes, showing Munc18c and b-tomosyn-1 binding to
syntaxin-4 [113]. Further studies will need to clarify whether other components are
required so that Munc18 can co-exist with tomosyn-1 in the same complexes. It is
generally thought that tomosyn-1 functions by interacting with t-SNAREs and blocking
v-SNARE binding, thus prevent the formation of fusogenic SNARE complexes [98]. The
syntaxin-2/SNAP-23 complex, but not syntaxin-4/SNAP-23, was associated with
tomosyn-1, Munc18b, and VAMP-8 (R-SNARE). This data suggests that tomosyn-1
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could exist in the same complex with VAMP. Similar observations have been reported
by Widberg et al. [113]. In adipocytes, Munc18c, but not Munc18b, associates with
tomosyn-1 and the SNARE complex (syntaxin-4/SNAP-23/VAMP-2), suggesting
specific tomosyn-1/Munc18s pairings in different tissue are important for fusogenic
SNARE complex formation.
VAMP-8, SNAP-23, and syntaxin-11 are the primary v- and t-SNAREs required
for platelet secretion [40, 41, 46].

In vitro complex pulldown assay showed that

tomosyn-1

syntaxin-2/SNAP-23

was

associated

with

heterodimers (Figure 4-1A, -1B).

and

syntaxin-4/SNAP-23

Experiments were designed to determine if

endogenous tomosyn-1 was capable of interacting with endogenous core SNARE
machinery components, which include syntaxin-11, SNAP-23, and VAMP-8 in platelets.
Both resting and thrombin-activated human platelets were lysed in Triton X-100 and
immunoprecipitations were performed using control IgG and anti-tomosyn-1 monoclonal
antibodies. Three t-SNAREs, syntaxin-2, syntaxin-4, and SNAP-23, were found in the
tomosyn-1 immunoprecipitates, suggesting endogenous tomosyn-1 is associated with
endogenous syntaxin-2 or -4 / SNAP-23 complexes. This is consistent with our in vitro
complex pulldown data (Figure 4-2). Endogenous tomosyn-1 co-immunoprecipitated
with syntaxin-11 from both resting and thrombin-activated platelet extracts, indicating
tomosyn-1 might be involved in platelet secretion through interaction with functional tSNAREs.

Association with VAMP-3 and VAMP-8 was not detectable, which is

consistent with the notion that R-SNARE motif of tomosyn-1 blocks v-SNARE binding
to t-SNAREs. It is likely that VAMP-8 and tomosyn-1 are present in two different
complexes since extra t-SNARE complexes were used in the pulldown assay. Taken
together, these data demonstrate that tomosyn-1 is associated with core SNARE complex
components, SNAP-23 and syntaxin-11 in activated platelets, suggesting tomosyn-1 may
regulate functional SNARE complex formation in vivo.

Tomosyn-1 is Phosphorylated and Partially Associated with Membrane
Tomosyn-1 can form stable complexes with t-SNARE heterodimers through its Cterminal R-SNARE domain [141]. It also has been shown that neuronal tomosyn-1 is
phosphorylated at Ser-724 by PKA and the PKA-catalyzed phosphorylation of tomosyn-1
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enhances neurotransmitter release through increased formation of the SNARE complex
[111]. Thus, tomosyn-1 could be regulated by phosphorylation. In platelets, PKA is
activated in resting cells while PKC is activated upon. To address the potential role of
tomosyn-1 phosphorylation in platelets, we investigated whether tomosyn-1 was
phosphorylated in vivo by using 32P metabolically-labeled platelets. Figure 4-3A shows
that phosphorylated tomosyn-1 was immunoprecipitated from both resting platelets
treated with or without PGI2 and platelets activated by thrombin. The phosphorylation
level is similar in resting and activated platelets. This result differs from that in neurons,
suggesting that tomosyn-1 phosphorylation may not be important in platelets. It is also
possible that PKA is responsible for tomosyn-1 phosphorylation in resting platelets while
PKC is associated with tomosyn-1 phosphorylation upon platelet activation, thus the level
of phosphoryation observed did not change. Further experiments will be required to
address this point
Tomosyn-1 is a cytosolic protein while SNAREs are membrane proteins. If
tomosyn-1 regulates SNARE complex formation through direct interaction with tSNAREs, a portion of tomosyn-1 should be detected associated with membranes. If
tomosyn-1 is a negative regulator in platelet through competing binding site with VAMP,
tomosyn-1 would expect to translocate from membrane upon platelet activation, which
allows SNARE complex formation and membrane fusion. To test this scenario and
determine whether tomosyn-1 is dissociated from the membranes upon platelet
activation, we performed membrane fractionation experiments. Tomosyn-1 was found to
be present in both membrane and cytosol fraction (Figure 4-3B). Membrane association
did not change upon thrombin stimulation, suggesting that tomosyn-1 does not dissociate
from membranes upon activation and secretion (Figure 4-3C).

The membrane

association increased upon NEM-treatment, suggesting tomosyn-1 may anchor to
membrane through association with SNAREs. This observation is consistent with a
previous report that tomosyn-1/syntaxin/SNAP-23 complexes can be dissembled by NSF
(which is NEM sensitive) [104]. As a control, SNAP-23 and syntaxin-4 membrane
association did not change since both proteins are membrane proteins. In summary,
unlike neuronal tomosyn-1, which behaves as a negative regulator through PKA
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phosphoryation, phosphorylation and membrane association of platelet tomosyn-1 do not
change upon stimulation, suggesting tomosyn-1 may have a different role in platelets.

Tomosyn-1 is Important for Platelet Secretion
To address whether tomosyn-1 plays a role in platelet secretion, we examined
release from intact, tomosyn-1 KO mouse platelets. To exclude non-specific effects to
the secretory machinery due to a loss of tomosyn-1, washed platelet extracts from
tomosyn-1 KO (Tomo KO) and wild type littermates (Wt) were prepared and probed by
western blotting analysis. The protein levels of fifteen other secretory components were
not significantly altered by the deletion of tomosyn-1 (Figure 4-4A). A thrombin titration
experiment was performed using a 1 min incubation time (Figure 4-4B). The secretion
from α-granules and lysosomes was significantly decreased by the loss of tomosyn-1
compared with wild type, suggesting that tomosyn-1 is required for release from these
two granules. The release from dense granules was slightly inhibited, suggesting that
other components are compensating for the loss of tomosyn-1 or that it is not required.
To confirm whether tomosyn-1 is required for platelet exocytosis, we further
analyzed dense granule secretion from tomosyn-1 null platelets by using lumiaggregometry.

Figure 4-5, A-D and F-H shows the aggregation traces for washed

platelets (control, black traces; patient, gray traces) stimulated with 10 µg/mL collagen,
100 µM PAR4, 100 nM A23187, convulxin, and thrombin (0.025, 0.05, 0.1 U/mL). As
can be seen there is a significant defect in aggregation for the tomosyn-1 deficient
platelets. Concomitantly, ATP release from dense granules was significantly inhibited as
measured with luciferin/luciferase-induced luminescence (Figure 4-5, a-d and f-h).
Figure 4-5, E and I show in bar graph format, the release of ATP from dense granule
stimulated with different agonists. Secretion induced by the calcium ionphore, A23187,
is impaired, suggesting that the secretion defect seen on tomosyn-1 deficient platelets is
caused by the final SNARE-mediated fusion step and not at some upstream signaling
step.
To further confirm that the secretion defect, we also performed flow cytometry
analysis. P-selectin and LAMP-1 are integral membrane proteins in α-granules and
lysosome. Their exposure at the platelet surface is widely used as a metric for α-granule
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and lysosome exocytosis.

Compared to normal control and resting platelets, the

geometric mean fluorescence intensity (GMFI) of staining for P-selectin and LAMP-1 on
tomosyn-1 deficient platelets only slightly increased upon stimulation with 0.1 U/mL
thrombin (Figure 4-6, A-B). When quantified, the P-selectin and LAMP-1 staining on
tomosyn-1 null platelets was 2 fold less than those of wild type controls, suggesting that
release from α-granule and lysosome is significantly inhibited.
To explore whether loss of tomosyn-1 affects granule biogenesis, we compared
the levels of several granule markers. The level of the dense granule marker, serotonin
and the lysosome marker, β-hexosaminidase was not significantly different (Figure 44B). There were 2538 ± 66 CPM/2.5×108 from control platelets (n=12) and 3083 ± 91
CPM/2.5×108 from tomosyn-1 deficient platelets (n=24) for serotonin. The level of βhexosamidase was 64 ± 6 U/2.5×108 (Wt, n=12) vs. 60 ± 4 U/2.5×108 (Tomo KO, n=12).
The level of α-granule marker, PF4, was reduced 3 fold in tomosyn-1 deficient platelets:
1771 ± 184 pg/2.5×108 (Wt, n=12) vs. 573 ± 82 pg/2.5×108 (Tomo KO, n=12),
suggesting loss of tomosyn-1 causes reduction in intra-platelet PF4 storage. Further
studies are required to clarify if the observed reduction is caused by biosynthesis or
trafficking. Because the secretion assay is determined as percentage secretion, the PF4
storage level does not affect the result that there is an α-granule release defect in the
tomosyn-1 KO platelets.
To exclude that the observed secretion defect is caused by signaling, we examined
two important platelet activation markers: platelet cytoskeletal reorganization and
integrin αIIbβ3 activation. Activated αIIbβ3 was measured by flow cytometry analysis
using the JonA antibody. In Figure 4-4C, the histogram displays both JonA binding
curves for thrombin activated platelets (grey trace) from control and tomosyn-1 KO
platelets. There was no significant difference between wild type and the tomosyn-1 KO
platelets, which was confirmed by quantification (right panel of Figure 4-4C), suggesting
that tomosyn-1 depletion does not impair platelet αIIbβ3 inside-out signaling. In sum,
tomosyn-1 deficiency inhibited platelet secretion without affecting integrin activation,
granule centralization, platelet aggregation, and granule genesis, indicating tomosyn-1 is
important for platelet exocytosis.
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Tomosyn-1 is Important for Hemostasis and Thrombosis
The primary function of platelets is in hemostasis. To study whether deletion of
tomosyn-1 affects thrombosis and hemostasis, we used two in vivo assays. First, tailbleeding time tests were performed on 5-6 weeks old littermates generated from
tomosyn-1 heterozygous siblings. In Figure 4-7A, among 24 tomosyn-1 KO mice we
tested, only three mice had short or normal bleeding times, the remaining 21 mice bled
for more than ten minutes. The wild type with the same background showed normal
bleeding time with a median bleeding time of 226.4 ± 37.3 seconds (n=19).

This

prolonged tail-bleeding time in tomosyn-1 KO mice demonstrates that tomosyn-1 is
required for hemostasis and suggests that tomosyn-1 plays a positive role in platelet
secretion and hemostasis.
To further confirm that this robust in vivo, phenotype was due to loss of tomosyn1, we utilized the carotid artery, FeCl3-injury thrombosis model. The model looks at
thrombosis in response to endothelial cell damage by FeCl3 and measured to the time
required for carotid artery occlusion post-damage induction. In agreement with the
prolonged tail bleeding times, there was a robust thrombosis defect in tomosyn-1 deletion
mice as compared to wild type littermates (Figure 4-7B). The time to occlusion in wild
type littermates was around 2.7 minutes. Surprisingly, under the same condition, the
occlusion time for tomosyn-1 deficient mice was not observed, except one mouse around
7 minutes. These in vivo data provide strong evidence that tomosyn-1 is required for
platelet secretion, hemostasis, and thrombosis.

Discussion:
In summary, tomosyn-1 is present and phosphorylated in platelets. Tomosyn-1
was associated with the endogenous functional t-SNARE heterodimer, syntaxin11/SNAP-23 in platelets. Deletion of tomosyn-1 in platelets reduced platelet secretion
and thus impaired hemostasis and thrombosis. It is clear that tomosyn-1 is present in
platelets and important for platelet secretion, hemostasis, and thrombosis. In agreement
with previous studies showing tomosyn-1 interacts with t-SNARE heterodimers [104,
113, 141], tomosyn-1 was found associated with syntaxin/SNAP-23 heterodimers (Figure
4-1A, -1B) in vitro.

In particular, tomosyn-1 was found associated with syntaxin-
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11/SNAP-23 heterodimers in platelets (Figure 4-2). Studies have shown that incubating
cells with NEM could inhibit NSF [142, 143]. This enzyme has been suggested to
catalyze the disassembly of tomosyn-1/SNARE complexes. We observed an increase in
tomosyn-1 membrane association upon NEM-treatment, supporting the notion that
tomosyn-1 was associated with membranes through formation stable complexes with tSNAREs (Figure 4-3B, -3C). Tomosyn-1 is believed to be a negative regulator of
neurotransmitter release through its R-SNARE motif and through its phosphoryation by
PKA [98]. If this is the case in platelets, we would expect to see tomosyn-1 translocate to
the cytosol and phosphorylated upon platelet activation. Surprisingly, we did not find
that tomosyn-1 dissociated from membrane into the cytosol and tomosyn-1
phosphorylation was not changed upon stimulation. These data suggest that tomosyn’s
function in platelets may be different that in neurons. Our secretion data support this
contention. Taken together, our in vitro data does not support negative role for tomosyn1 in platelets.
Tomosyn-1 is important for platelet secretion from α-granules and lysosomes.
Further, tomosyn-1 is required for hemostasis and thrombosis. Overall, tomosyn-1 is
important for physiological platelet function and hemostasis, suggesting that tomosyn-1
plays a positive role in platelet exocytosis, possible through interaction with syntaxin11/SNAP-23.
Originally tomosyn-1 was shown to disrupt the neuronal Munc18a/syntaxin-1a
complex by binding to syntaxin-1a and has thus been proposed to be a positive modulator
of SNARE complex formation [104].

It is possible that tomosyn-1 is required for

activating syntaxin by releasing syntaxin-11 from Munc18b into an open stage. Our
results, in agreement of Widberg et al [113], showed that all the components can still be
in a fusion complex which probably requires some conformational change for activation
of fusion. Another possibility is that tomosyn-2 might be important for neurotransmitter
release while tomosyn-1 is important for platelets and adipocyte exocytosis.

The

inhibitory phenotype shown in tomosyn-1 KO mice may reflect tomosyn-1 competition
with tomosyn-2 [107].

Moreover, there are conflicting results from neuronal field.

Tomosyn-1 knockdown in SCG neurons inhibits synaptic transmission [111]. It has also
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been shown that down regulation of tomosyn-1 reduced insulin secretion from an insulinsecreting INS-1E cell line [144].
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Table 4-1. MS of Syntaxin Complex Interacting Proteins
Sample

MS Score

Protein

T1

144

Tomosyn-1

T2

66

Tomosyn-1

T3

325

Munc18b

T4

259

Granuphilin

The specific interacting proteins from Figure 4-1, which were indicated on the top as T1T4 were excised from the gel and subjected to trypsin digestion. The samples were
spotted onto a matrix-assisted laser desorption ionization (MALDI) target plate. Both
mass spectrometry (MS) and tandem time-of-flight (TOF-TOF) spectra were acquired
and processed. The data were searched against the database using MASCOT software.
The MASCOT search results were shown.

96

97

Figure 0-1Figure 4-1: Tomosyn-1 is Present in Platelets

Figure 4-1. Tomosyn-1 is Present in Platelets. A) The indicated complexes were
produced in E.coli using the pRSFDuet plasmid with a S-tag peptide fused to the Cterminus of the syntaxin. Complexes are bound to S-Protein-Agarose beads through the
S-tag. After washing, the complex-bound beads were incubated with solubilized platelet
extracts. The beads were washed again, and then the proteins were eluted with SDSPAGE sample buffer. The eluted proteins were separated by SDS-PAGE and stained
with Sypro Ruby. The specific interacting proteins which were indicated on the top as
T1-T4 were excised from the gel and subjected to trypsin digestion. The samples were
spotted onto a matrix-assisted laser desorption ionization (MALDI) target plate. Both
mass spectrometry (MS) and tandem time-of-flight (TOF-TOF) spectra were acquired
and processed. The data were searched against the database using MASCOT software.
The MASCOT search results are shown on the Table 4-1. B) The indicated complexes
were produced in E.coli using the pRSFDuet plasmid with a S-tag peptide fused to the Cterminus of the syntaxin. Solubilized platelet extracts were incubated with the different
complexes and the resulting material was recovered on S-Protein-Agarose.

After

washing, the proteins were eluted and probed by western blotting with the antibodies to
the indicated proteins. C) RT-PCR using platelet-derived RNA with tomosyn-1 isoformspecific primers shows only expression of PCR product corresponding to m-tomosyn-1
mRNAs while not to b- and s-tomosyn-1 mRNAs in human platelets. Marker = 1-kb
DNA ladder.
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Table 2Table 4-1. MS of Syntaxin Complex Interacting Proteins

Figure 0-2Figure 4-2: Tomosyn-1 is Associated with Platelet Core SNARE Fusion Complexes

Figure 4-2. Tomosyn-1 is Associated with Platelet Core SNARE Fusion Complexes.
Platelet extracts (Plt Ext.) from resting (R) or thrombin stimulated platelets (S) were
prepared by solubilization with 1% Triton-100. After clarification, platelet extracts were
incubated with anti-tomosyn-1 murine monoclonal antibody or an IgG (1:1 ratio mixture
of murine and rabbit IgG) control for 4 h at 4°C. The immune complexes were recovered
with Protein-G-Aagarose. The bound proteins were eluted and separated by SDS-PAGE,
followed by western blotting with the indicated antibodies.
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Figure 0-3Figure 4-3: Tomosyn-1 is Phosphorylated in Both Resting and Activatied Platelets and Membrane
Association Increases upon NEM Treatment

Figure 4-3. Tomosyn-1 is Phosphorylated in Both Resting and Activated Platelets
and Membrane Association Increases upon NEM Treatment. A) Metabolically [32P]labeled platelets were stimulated with or without thrombin for 2 min. Platelets were
solublized with 1% Triton-100 to make platelet extract. Protein A Sepharose, conjugated
with anti-tomosyn-1 monoclonal antibodies were incubated with the labeled platelet
extract. After washing, the bound proteins were analyzed with SDS-PAGE, followed by
Phosphor Imaging and western blot for tomosyn-1. B) Resting and thrombin activated
platelets treated with or without NEM were sonicated, followed by centrifugation to
separate membrane and cytosol fractions. The equivalent amount of two fractions were
loaded and analyzed with SDS-PAGE, followed by western blotting for the indicated
proteins. ImageQuant 5.2 software was used to analysis of immunolabeled bands. The
data are presented as means ± SD.
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Figure 0-4Figure 4-4: Tomosyn-1 Deficient Murine Platelets Have Secretion Defects

Figure 4-4. Tomosyn-1 Deficient Murine Platelets Have Secretion Defects.

A)

Platelet extracts (5.0 × 107 platelets/lane) from wild type (Wt) and tomosyn-1 KO (Tomo
KO) mice were probed by western blotting with the indicated antibodies. [3H]-5HT
labeled and washed platelets from tomosyn-1 null (red circle symbols) and Wt (black
square symbols) were prepared and incubated with 0.7 mM CaCl2 at RT for 5 min, prior
to activation with the indicated thrombin concentration for 1 min. Release of [3H]-5HT
from dense core granules, PF4 from α-granules, and β-hexosaminidase from lysosomes
was measured, and percent secretion was calculated. The points represent the average of
triplicate measurements and the standard deviation is indicated. The statistical analysis
was performed by ANOVA (GraphPad Prism 5), p<0.001.
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Figure 0-5Figure 4-5: Deletion of Tomosyn-1 in Platelets Affects ATP Release but Limited Effects on
Aggregation

Figure 4-5. Deletion of Tomosyn-1 in Platelets Affects ATP Release but has Limited
Effects on Aggregation. Washed platelets from Tomosyn-1 null (Tomo KO) and wild
type (Wt) mice were stimulated with collagen (5 µg/mL, A), PAR4 peptide (100 µM, B),
A23187 (10 nM, C), convulxin (10 µg/mL, D), or thrombin (0.025 U/mL, F; 0.05 U/mL,
G; 0.1 U/mL, H) for 2-3 minutes. The aggregation traces were monitored (A-D and F-H)
and concurrently the released ATP monitored by a luciferin/luciferase-induced
luminescence (a-d and f-h).

The absolute percentage ATP release comparing to

background PPP was graphed (E and I).
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Figure 0-6Figure 4-6: Depletion of Tomosyn-1 in Platelets Effects P-selectin and LAMP-1 exposure but not
intergrin activation

Figure 4-6. Depletion of Tomosyn-1 in Platelets Affects P-selectin and LAMP-1
Exposure but not Intergrin Activation. Washed platelets (1 × 108/mL) from wild type
(Wt) and tomosyn-1 null (Tomo KO) mice were stimulated with or without 0.1 U/mL
thrombin for 1 min and then incubated with FITC-conjugated anti-P-selectin, or FITCconjugated LAMP-1, or FITC-conjugated anti-integrin αIIbβ3, or PE-conjugated JonA
antibodies for 15 min at RT. The reactions were stopped by adding 10 volumes of 1%
formaldehyde for 30 min and the fluorescent intensities were measured by flow
cytometry. The data from a representative FACS run are shown and cumulative data was
graphed using Geo Mean Fluorescence Intensity (GMFI): P-selectin (A), LAMP-1 (B),
JonA (C), and GPIIbIIIa (D).
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Figure 0-7Figure 4-7: Tomosyn-1 Deficient Mice Have Bleeding Phenotype

Figure 4-7. Tomosyn-1 Deficient Mice Have Bleeding Phenotype.

Mice from

Tomosyn-1 null (Tomo KO) and wild type (Wt) littermates were used for tail-bleeding
time assay and FeCl3-induced arterial thrombosis.

The animal number, mean and

standard deviation are indicated (p<0.0001, ANOVA). A) Tail bleeding times were
measured after tail transection. The tail tips were used for genotyping. B) Occlusion
time in FeCl3-induced arterial thrombosis test.
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Figure 4-8. Western Blot Analysis of Interacting Proteins of Syntaxin Containing
Complexes. The indicated complexes were produced in E.coli using the pDuet plasmid
with a S-tag peptide fused to the C-terminus of the syntaxin. Solubilized platelet extracts
were incubated with the different complexes and the resulting material was recovered on
S-Protein-Agarose. After washing, the proteins were eluted and probed by western
blotting with the antibodies to the proteins indicated on the left.

Copyright © Shaojing Ye 2012
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Chapter Five
Conclusions and Future Directions

The research presented in this dissertation demonstrates that syntaxin-11, rather
than syntaxin-2 or syntaxin-4, is the primary t-SNARE required for platelet secretion.
The enhanced α-granule secretion from syntaxin-2/4 double KO platelets suggests that
syntaxin-2 and syntaxin-4 could serve as secondary syntaxins for platelet secretion.
Given that endogenous syntaxin-11 was associated with SNAP-23 and VAMP-8 in
platelets, it seems plausible that syntaxin-11 forms fusogenic SNARE complexes
required for platelet secretion.
We have also added a novel component, tomosyn-1, to the list of proteins
involved in platelet secretion. Tomosyn-1 is associated with syntaxin-11 and SNAP-23
both in activated platelets and resting platelets, suggesting tomosyn-1 may be interact
with a fusogenic SNARE complex.

The studies of tomosyn-1 KO mice show that

tomosyn-1 is important for platelet secretion, at least for α-granule and lysosome release.
Moreover, tomosyn-1 is required for hemostasis and thrombosis. Overall, tomosyn-1 is
important for platelet function and hemostasis, suggesting that tomosyn-1 plays a positive
role in platelet exocytosis. My data suggest that its role could be through interactions
with syntaxin-11/SNAP-23 heterodimers. The mild defect of dense granule secretion
contrasts with the robust impairment of hemostasis, suggesting that tomosyn-1 is required
for normal platelet function and also suggests that there is more to uncover about the role
of tomosyn-1 in vivo. Clearly the data presented here show that controlling platelet
secretion without affecting signaling may be a therapeutic target for anti-platelet therapy
to control serious cardiovascular diseases, such as heart attack and stroke.

The Core SNARE Machinery in Platelet Secretion
It is generally believed that most regulated exocytosis is a SNARE-mediated
membrane fusion process. SNARE proteins are characterized by a conserved heptad
repeat region of approximately 60-70 residues in length, referred to as SNARE motif.
The energy from SNARE complex formation is believed to drive lipid bilayer fusion. A
functional SNARE complex comprises four SNARE motifs from synaptic SNARE
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proteins, forming a four-helix, coiled-coil structure [28, 145]. All physiological SNARE
complexes cotain one R- and three Q-(a, b, c) SNAREs as described in Chapter 1. In
platelets, both VAMP-8 (R) and SNAP-23 (Qbc) are required for platelet secretion, so the
functional SNARE complex should be the R-Qa-Qbc configuration. This suggests that
Vtib (Qb) is not likely to be a component of the functional SNARE complexes in
platelets. The studies from Chapter 3 clearly demonstrated that syntaxin-11 is required
for platelet exocytosis and thus is the most likely Qa-SNARE candidate. Studies also
suggested that syntaxin-11, SNAP-23, and VAMP-8 are present in the same complex as
demonstrate by immunoprecipation with syntaxin-11 antibodies (Chapter 3) and SNAP23 antibodies [Karim et al, in preparation].
Syntaxin-11 is much more important for dense granule and α-granule release than
for lysosome release, which suggests that syntaxin-11 mediates at least one common step
that is important for both efficient and rapid dense granule release and less rapid but the
more abundant α-granule release. Given the clinical bleeding diathesis observed with this
patient (Filipovich, personal communication), this step must be vital for hemostasis.
Syntaxin-11 also must play a role in lysosome release; but, unlike dense granule and αgranule release, secretion from lysosomes was not completely eliminated in syntaxin-11
deficient human platelets. Residual release from lysosomes indicates that a redundant
syntaxin compensates for the lack of syntaxin-11, though less efficiently. The potential
candidates are syntaxin-2 and -4, especially considering that the syntaxin-2/4 double
depletion mouse platelets had mild secretion enhancement for α-granule and lysosome
release. If syntaxin-2 or -4 serve as secondary syntaxins for lysosome release, it may not
be obvious in the single and double knockouts. As a comparison, deletion of VAMP-2
and/or-3 had no overt effect yet they could be shown to play a role when analyzing the
residual secretion from VAMP-8 KO platelets.
The data in Chapter 3, showing that syntaxin-2 and -4 are not critical for platelet
secretion, contradict previous reports from our laboratory and others [40, 41, 44]. The
discrepancy can be explained by a number of factors that stem from the use of antibodies
as inhibitors in permeabilized platelets. The large antibody molecules could sterically
block a functional SNARE or the antibody could cross react with other SNAREs. Based
on the observation that β-hexosaminidase and PF4 levels from syntaxin-2 and -4 double
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KO and syntaxin-11 deficient platelets are normal, syntaxin-2, -4, and -11 are almost
certainly not required for granule biogenesis. Thus the requirement for syntaxin-11 in
platelet secretion, shown in Chapter 3, could be attributed to a defect of vesicle priming
and/or fusion. To define the exact mechanism for syntaxin-11 in platelet exocytosis,
further studies are required, but clearly it is essential for secretion.
Platelet exocytosis represents a unique model to study vesicle trafficking because
platelets have three different granules with the three different types of cargo, release
rates, and delays post-stimulation.

This might suggest that three different types of

granule release events may use slightly different sets of SNAREs or regulatory proteins.
Loss of the primary v-SNARE, VAMP-8, shows differential effects on the three granule
secretion processes. Dense granule is the least affected in VAMP-8 deletion murine
platelets. However deficiency of syntaxin-11 totally abolishes both α-and dense granule
release but has a milder effect on lysosome release [Figure 3-17]. This suggests that
three different granule release processes may use different SNARE regulators or that
certain t-SNARE regulators are more critical for the rapid release.

The supportive

evidence for SNARE regulators playing a critical role in granule release comes from the
studies of Munc13-4 and tomosyn-1. The loss of Munc13-4 in platelets has a greater
effect on dense granule secretion than on α-granule and lysosome release [48]. The
newly described regulatory protein tomosyn-1 (Chapter 4) appears to play a more
important role for α-granule and lysosome release than dense granule release [Figure 44]. Further studies on regulatory proteins will identify whether different regulatory
proteins interact with specific SNAREs, thus playing a differential role in specific
granule release.
Based on the classic neuronal SNARE complex (syntaxin-1/SNAP-25/VAMP-2),
it is expected that both Qa and R-SNARE need TMDs. However, syntaxin-11 does not
contain a TMD. Since studies from Chapter 3 demonstrate that syntaxin-11 is required
for platelet secretion, we hypothesize that the functional SNARE complex in platelets is
syntaxin-11 (Qa), SNAP-23 (Qbc), and VAMP-8 (R). This is supported by the fact that
syntaxin-11 associates with SNAP-23 and VAMP-8 in (Figure 3-19). Thus it would
appear that syntaxin-11 forms a functional SNARE complex required for all three granule
release. Moreover it has been demonstrated that syntaxin-11 is required for exocytosis
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from lymphocytes [146]. Although the exact membrane anchoring is still unknown,
studies [37] have suggested that the majority of syntaxin-11 is anchored to membranes
and may be so via palmitoylation of C-terminal cysteine residues. This is significant
because studies show that t-SNARE membrane anchor activity, and thus fusogenicity, is
governed by the overall degree of hydrophobicity of the added modification [39]. A tSNARE complex anchored only by phosphatidyl-ethanolamine (PE)-linked SNAP-25
(involving up to four PE molecules per SNAP-25) and syntaxin-1 cytoplasmic domain is
enough to drive membrane fusion [39]. Studies [36, 39, 147] have suggested that long
prenyl groups (~C55) can replace the TMD of VAMP-2 in proteoliposome fusion. To test
our hypothesis, two types of proteoliposomes: t-SNARE (SNAP-23 and PE-linked
syntaxin-11 containing different number of C-terminal cysteine residues or a C-terminal
domain replaced by the TMD of syntaxin-2) containing vesicles and v-SNARE (VAMP8) containing vesicles can be tested for fusogenicity [33]. Fusion efficiency is expected
to be correlated with the number of modified C-terminal cysteine residues of syntaxin-11
and concentration of cholesterol in liposome. Considering syntaxin-11, but not syntaxin2 and -4, is required for platelet secretion and that platelet secretion is believed to happen
at the OCS, which is cholesterol rich membrane region, one expectation should be that
lipid-modified syntaxin-11 is more fusogenic than that with chimeric syntaxin-2 TMD.
Finally the latest discovery of Vti1b in platelets opens another possibility. The
typical core fusion complexes are likely to have a similar parallel four-helical bundle
structure, but in some cases the two α-helical SNARE domains provided by SNAP-25
may be replaced by the SNARE domains of other members of the syntaxin family. For
example, VAMP-8 complexes with syntaxin-7 (Qa), Vti1b (Qb), and syntaxin-8 (Qc) and
VAMP-4 complexes with syntaxin-16, Vti1a, and syntaxin-6 [148, 149]. At this point,
we cannot fully exclude that syntaxin-2 is in the fusion complex for the final step since
endogenous syntaxin-2 (Qa) might be present in the endogenous syntaxin-11 (Qa)
precipitates [Figure 3-19].

Another candidate is Vti1b (Qb).

Although Vti1b is

negatively regulated by syntaxin-11 in macrophage [77], it might be in similar complexes
in platelets and thereby compensate for the lack of a syntaxin-11transmembrane domain.
Further studies are required to address these possibilities.
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Taken together, a model consistent with our data shows the functional core
SNARE machinery includes VAMP-8 on granule membranes and SNAP-23 and
syntaxin-11 on plasma membrane in platelets (Figure 5-1). Syntaxin-11 is the most
abundant t-SNAREs of four known syntaxins in platelets (Table 5-1); suggesting
syntaxin-11 could be the critical t-SNARE just like VAMP-8 is the primary v-SNAREs
[46]. In sum, all the evidence support that syntaxin-11 is the primary t-SNARE required
for platelet secretion.

The SNARE Complex Regulation for Platelet Secretion
Munc18s are cytosolic proteins that belong to the evolutionally conserved SM
family which is required for vesicle trafficking events [79, 136, 150]. SM proteins act as
syntaxin-specific chaperones and may contribute to matching cognate v- and t-SNARE to
form fusogenic trans-SNARE complexes [151]. Among the three SM isoforms present
in platelets: Munc18 (a, b, c) [47, 63, 78], Munc18b is the most abundant [Al-Hawas et
al. in preparation]. Moreover when using t-SNARE heterodimer [Figure 4-1] or SNARE
complex [47], Munc18b is the only Munc18 identified in the pull-downs from human
platelet extracts. More importantly, human platelets from Munc18b mutant patients
(FHL5) show a robust secretion defect from all three granules [50]. Data from our
laboratory show that platelets from Munc18b deficient patients have defects in the release
of serotonin, PF4, and β-hexosaminidase [Al-Hawas et al. in preparation]. It will be
interesting to know if the platelet secretion impairment in certain FHL5 patients is caused
by dominant-negative Munc18b mutations (or loss of the protein due to protein
instability). If this is true, inhibitory peptides of based on Munc18b could be a new drug
candidate to modulate thrombosis. Consistently, peptides based on a conserved region of
Munc18 did prove to be effective inhibitors of secretion when introduced into
permeabilized human platelets [47].
Since Munc18b is required for all three granule secretion events, further exploring
the mechanism of Munc18b in platelet secretion will help to identify other SNARE
machinery components and understand how Munc18b specifically interacts with tSNAREs or v-SNARE to promote specific SNARE complex formation. This might also
shed light on how secretion is coupled to the platelet signaling pathways. Munc18b may
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be a syntaxin-11-specific partner since our unpublished data showed that platelets from
FHL5 patient (which had no Munc18b) had reduced levels of syntaxin-11. Syntaxin-11deficient platelets from a FHL4 patient display a robust secretion defects while Munc18b
protein level is only partially reduced [Figure 3-17A]. This prompts speculation that
syntaxin-11 is an absolutely required component for secretion while Munc18b is required
for syntaxin-11 stability (Figure 5-1). This may indicate that Munc18b functions as a
specific chaperone for syntaxin-11.
Given that loss of Munc18b affects syntaxin-11, it is formally possible that loss of
syntaxin-11 contributes to the observed phenotype in FHL5 patients, which lack
Munc18b. This would be consistent with the phenotype from syntaxin-11 deficient
platelets from a FHL4 patient in this thesis. One hypothesis is Munc18b serves solely a
syntaxin-11 chaperone. To test this hypothesis, more characterization of FHL5 platelets
is required. A correlation analysis should be performed to link the types of Munc18b
mutations to the levels of secretion defect to determine whether the severe secretion
defect is caused by certain Munc18b mutations.

Another experiment could use

mutagenesis to generate two kinds of Munc18b mutations that differentially affect
syntaxin-11 protein levels and then introduction into megakaryocytes lacking endogenous
Munc18b and syntaxin-11.

If our hypothesis is right, we would expect to see the

secretion defect corrects with the syntaxin-11 protein levels. However, it should be noted
that Munc18b heterozygous patients show a partial secretion phenotype and no reduction
in syntaxin-11, so it seems possible that Munc18b could play other roles as a limiting
component of the secretion pathway (Al Hawas et al. in preparation). Further studies are
required to discriminate whether Munc18b serves solely a chaperone or is also a core
regulator for functional specific SNARE complex formation in platelet secretion.
Although syntaxin-11 stability is dependent on Munc18b, Munc18b is not solely a
syntaxin-11-specific partner. Loss of syntaxin-11 in platelets did not significantly affect
Munc18b protein levels as shown in Figure 3-17A, suggesting that syntaxin-11 is not
required for Munc18b expression and stability. Moreover Munc18b can specifically
interact with syntaxin-2/SNAP-23 complex but not the syntaxin-4/SNAP-23 complex
[Figure 4-1], supporting the idea that Munc18b might also be a chaperone for syntaxin-2.
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Tomosyn in Platelets
By using syntaxin-containing complexes, we purified tomosyn-1 from platelet
extracts. Tomosyn-1 is a cytosolic protein, was originally identified as a syntaxinbinding protein.

It has been shown to disrupt the neuronal Munc18a/syntaxin-1a

complex and thus was proposed to be a positive modulator of SNARE complex formation
[104]. The results from this work support the hypothesis that tomosyn-1 is a positive
regulator for platelet granule secretion. Results in this work clearly show that tomosyn-1
KO mice have a bleeding diathesis and tomosyn-1 is required for platelet secretion from
at least α-granules and lysosomes. Overall, tomosyn-1 is important for platelet function
and for hemostasis though the mechanism is still elusive. In agreement with previous
studies [104, 113, 141], tomosyn-1 is associated with the membrane through interactions
with syntaxin/SNAP-23 heterodimers in platelets. Tomosyn-1 has also been thought to
bridge the fusion machinery to a signaling event. It has been shown that phosphorylation
of tomosyn-1 by PKA [98] is important for regulation of SNARE complex formation
upon stimulation in neuron. Indeed, tomosyn-1 is phosphorylated in platelets but this
phosphorylation does not appear to change during platelet activation. This suggests that
tomosyn-1 phosphorylation may not be a viable secretion control pathway in platelets.
Tomosyn-1 also can form complexes with syntaxin-11 and SNAP-23. Widberg et al
[113] and our syntaxin-1\SNAP-23 pull down experiments (Figure 4-1A) show that the
fusion components, which include VAMP-8, syntaxin-11, SNAP23, Munc18b, and
tomosyn-1 can form a large complex. It is possible that tomosyn-1 is required for
activating syntaxins by releasing syntaxin-11 from the Munc18b/closed syntaxin stage
into an open conformation.
However, the mechanism that tomosyn-1 plays in different tissues is elusive. The
studies of tomosyn-1 KO mice clearly show that tomosyn-1 is a negative regulator of
neurotransmitter release but a positive regulator for platelet exocytosis. It is possible that
this inconsistency is caused by tissue-specific factors that have yet to be identified.
Consistently, phosphorylation of tomosyn-1 appears different in neuron than in platelets.
Tomosyn-1 is similarly phosphorylated in both resting and activated platelets while
neuronal tomosyn-1 is phosphorylated by PKA only upon stimulation. The difference
could be caused by the specific kinases in different tissue. Upon stimulation, PKA is the
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active form in neurons while PKC is activated in platelets. It is possible that tomosyn-1
is phosphorylated by PKA in resting platelets and by PKC in activated platelets, but the
sites of phosphorylation are different. Another possibility is that tomosyn-2 might be
important for neurotransmitter release while tomosyn-1 is important for platelets and
adipocytes exocytosis. The inhibitory phenotype shown in tomosyn-1 KO mice may be a
result of tomosyn-1 competition with tomosyn-2 [107]. Future studies should focus on
the different mechanism for tomosyn-1 as negative role in neurotransmitter release and as
positive role in platelet exocytosis. It is important to determine if tomosyn-1 serves as
place holder for VAMPs and/or is keeping the t-SNAREs in an activated state. These
experiments will help us understand the differential roles of tomosyn-1 in different cell
types.

The phenotype observed from tomosyn-1 KO mice is similar to that in the

granuphilin KO mice [92]. Finally, it is also possible that tomosyn-1 sequesters tSNAREs from the functional fusion complex or secretion active zones using unknown
mechanisms.
The last possible mechanism for tomosyn-1 regulating platelet secretion can be
through interaction with cytoskeletal components.

Future studies are required to

understand the molecular mechanism of tomosyn-1 on platelet secretion and
cardiovascular diseases. Because endothelial cells are another key regulator for initiation
of thrombus formation by providing vWF for platelet adhesion and activation, bone
marrow transplantation will allow differentiation of the role of tomosyn-1 in platelets and
endothelial cells. We expect that vWF release from Weibel-Palade body (WPB) will be
defective considering tomosyn-1 is ubiquitously expressed in different tissue. The robust
bleeding problem and impaired thrombosis formation could be due to a defect in
endothelial cells.

Platelet Rabs
Rab GTPases and their effectors, which coordinate vesicle attachment and the
subsequent assembly of cognate v- and t-SNARE complexes, play a key role in
exocytosis [152]. The Rab27 family is involved in both dense granule biogenesis in
megakaryocytes and platelet secretion [90]. In platelets, it has been shown that the
majority of Rab27 is associated with dense granules while a smaller portion is associated
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with the plasma membrane. Rab27a/b double KO murine platelets display a severe
defect in serotonin secretion [86]. The exact role of Rab27a/b in the regulation of dense
granules instead of α-granules remains unclear. Presumably the multiple-functions of
Rab27 act through recruiting different effectors. One of Rab27’s effectors, Munc13-4, is
required for platelet secretion [48, 49], suggesting Rab27s and their effectors are required
for dense granule exocytosis. It is also possible that Rab27s interact with unknown
factors which are important for dense granule package and trafficking, given the fact that
deficiency of Munc13-4 also affects α-granule release.

The role of Munc13-4 and

Rab27s in platelets is not fully understood since Munc13-4 is not required for granule
biogenesis while Rab27s are[48]. Munc13-4 is also associated with α-granule release
while Rab27s are not.

Further exploration of the mechanisms for Rabs in platelet

secretion will clarify whether different granules require specific sets of Rab proteins or
effectors.

Rab27 Effectors in Platelets
Munc13s are widely believed to serve as key vesicle priming factors.

The

strongest evidence for this is from genetic ablation of both Munc13-1 and Munc13-2,
which completely abolishes the synaptic vesicle priming and release [87, 88]. Mice
lacking Munc13-4 have a bleeding diathesis and release from dense granules is totally
abolished while the release from α-granules and lysosomes is severely impaired [48].
This indicates that Munc13-4 mediates at least one step that is uniquely required for rapid
dense granule release, and that this step is also critical for hemostasis in vivo. The
residual secretion from α-granules and lysosomes could be compensated for by other
Munc13 family members or other Rab27 effectors. The syntaxin containing complex
pull-down experiment in this work (Chapter 4) discovered that both of Munc13-1 and
Munc13-4 could interact with Munc18a/syntaxin-2 complex specifically in platelets.
However, only Munc13-4 is critical for platelet secretion [48]. Compared with other
Munc13s, Munc13-4 does not contain a C1 domain, but does have two C2 domains and a
MHD domain. The observations that mutations in the MHD domain or deletion of the
C2B domain [89] and Munc13-4 peptides without C2B domain potently inhibit platelet
secretion [48] suggest that both the MHD domain and the C2B domain are important for

119

its function. It is possible that the MHD domain is required for interaction with important
secretory machinery components while the C2B domain is important for anchoring to the
plasma membrane or for regulating membrane fusion in response to Ca2+ signaling.
Identifying the key interacting partners of Munc13-4 will be an important step for us to
understand the SNARE complex formation or membrane fusion upon stimulation. One
possible candidate is Munc18b since patients with mutations in Munc18b have blocked
secretion of all three granules.

This suggests that Munc18b is downstream in the

secretion pathway and is shared by all three granule release events.
Other Munc13 family members, DOC2α or granuphilin are candidates for
possible contributors to the steps required for the residual release of α-granule and
lysosome content upon loss of Munc13-4. Granuphilin is a known Rab27 effector; its
presence in platelets was first identified by using Munc18a/syntaxin-2 complex (Chapter
4). The role of granuphilin in platelets has not been investigated. It will be interesting to
know whether granuphilin is negatively regulating platelet secretion considering
deficiency of granuphilin enhances β-cell exocytosis [92].

Future studies should

determine the mechanism of Rab27 effectors on platelet exocytosis. One expectation is
that dense granules contain a specific molecule, such as Rab27, which is important for the
specific release pathway that it is required for. Identification of new interacting partners
that are directly or indirectly associated with Rab27 effectors and the SNARE/Munc18
complex will help us to dissect the molecular mechanism of vesicle priming.

Endocytosis
Endocytosis is important for platelet function though it is uncharacterized at the
molecular level. Several granule cargo proteins are taken up by platelets from plasma via
an endocytic pathway. Several mechanisms of endocytosis have been suggested. It has
been shown that plasma proteins can bind to a platelet surface receptor and subsequently
be internalized via a clathrin-dependent process.

The best example is uptake of

fibrinogen via integrin αIIbβ3 [153-157]. The endocytosis of factor V by megakaryocytes
is through a two-receptor system mediating specific endocytosis by binding to a specific
factor V receptor and then to the low-density lipoprotein receptor-related protein-1 (LRP1) [158]. Some plasma proteins, such as immunoglobulins and albumin, can incorporated
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into α-granules via pinocytosis [159]. Exploration of endocytosis in platelets will unveil
a pathway, fusion machinery, and connections to exocytosis.

Our observation that

platelets from syntaxin-2/4 double KO mice have lower levels of fibrinogen (Figure 3-13)
supports the notion that there is an endocytosis defect caused by the loss of these two
syntaxins. This indicates that syntaxin-2 and -4 may be more important in platelet
endocytosis than in exocytosis. Thus the syntaxin-2 and -4 double KO mouse models
will be an ideal tool to study platelet endocytosis. It will also be interesting to determine
whether both pathways share common SNARE proteins. If they have common SNAREs,
what other factors coordinate the equilibrium between the two different pathways. Given
syntaxin-11 was discovered as an endosomal trafficking t-SNARE [37], we expect that
syntaxin-11 may be involved in the late stage of endocytosis pathway, for example the
fusion between late endosome with lysosome. Alternatively, identification of the tissue
specific factors that direct syntaxin usage in endocytosis or exocytosis will not only be an
important biological concept, but may also lead to the discovery of a new therapeutic
target for cardiovascular diseases.

Hemostasis and Thrombosis
Platelets play a vital role in hemostasis upon vascular injury.

Damage to

endothelial cells causes the exposure of agonists, such as collagen and vWF, which
initiate platelet adhesion and activation. Activated platelets release granule contents from
three different types of granules. Each granule type carries specific molecules that
promote thrombus formation.

Dense granules contain serotonin, ATP, ADP, and

calcium, which are important for vascular contraction and thrombogenesis [1, 13]. αgranules contain many kinds of factors, such as PDGF, VEGF, chemokines, adhesive
molecules (eg. vWF and fibrinogen), and coagulation factors (eg. Factor v). These
factors are not only important for clot stabilization but also play a role in wound repair.
The released cargo from lysosomes is thought to be involved in fibrinolysis [1, 5].
Although platelet secretion is essential for hemostasis and thrombosis, little is known
about the regulatory elements that control it. Platelet secretory machinery contains three
core SNAREs and more than four regulatory proteins that control when, where, and how
SNARE complexes assemble upon stimulation [5, 13, 47, 48, 50, 64]. Deficiency of the
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primary t-SNARE or v-SNARE results in bleeding problems. For example, VAMP-8
null mice form smaller and delayed thrombus [13, 46] while syntaxin-11 and Munc18b
deficient patients have severe bleeding problems [160]. Loss of regulatory proteins, such
as Munc18b [50], Munc13-4 [48], and tomosyn-1 [Chapter 4], causes prolonged bleeding
time and impairs thrombosis formation. Future studies on how these regulatory proteins
affect hemostasis and thrombosis beyond the regulation of SNARE complex formation
might lead to new drug discovery to control thrombosis without damage to normal
hemostasis.

The Platelet Secretion in FLH Diagnosis
Hemophagocytic lymphohistiocytosis (HLH) is a rare immune disorder
characterized by proliferation of cells of the mononuclear phagocyte system (histiocytes)
and hyperinflammation [161-163].

The typical clinical features include fever,

hepatosplenomegaly, lymphadenopathy, jaundice, rash, and laboratory findings of
lymphocytosis, histiocytosis and hemophagocytosis. This clinical syndrome comprises
the primary (genetic) HLH and secondary (acquired) HLH. The genetic HLH can be
classified as FHL and immune deficient associated HLH, such as Griscelli syndrome 2
(GS-2), X-linked proliferative syndrome (XLP), Chediak-Higashi syndrome (CHS)
according to the newest classification [161].

Acquired HLH appears as a severe

complication of certain virus infection, such as Epstein–Barr virus, of autoimmune
diseases [161].
Five FHL (1-5) have been categorized. FHL1 is associated with a potential gene
locus (9q21.3-q22) with unidentified specific gene [164]. The perforin gene (PFR1)
mutations at 10q21-22 locus were described to be the first causative gene for FHL2
[165]. Perforin is essential for T-cell function and is released from secretory granules
and is required for delivering granzyme to induce apoptotic death of target cells. This
pore-former plays a critical role in maintaining immune homeostasis [166]. Recently
genes mutated in Munc13-4 (FHL3), Syntaxin-11 (FHL4), and Munc18b (FHL5) have
been shown to be involved in cytotoxic granule exocytosis from CTL and NK cells [89,
167, 168].

Concomitantly these gene are also critical for platelet exocytosis and

deficiency of these proteins cause granule release defects [48, 50] and Chapter 4.
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Detection of perforin, Munc13-4, syntaxin-11, and Munc18b expression in NK cells with
FACS or western blotting analysis are reliable methods to screen for FHL2-5. However,
these analyses are not available to some patients with extremely reduced NK cell
numbers. Compared to NK and CTL, platelets are more abundant. There are clinically
established tools to analyze platelet function, such as aggregometry and electron
microscopy. Platelet function analysis is a practicable and reliable method to diagnose at
least FHL3-5. Combination of platelet function analysis will also provide suggestions for
the cause of other genetic HLH. However, it may not apply for acquired HLH.
Although a consensus set of criteria for diagnosis of HLH was established in 2004
by the Histiocyte Society and was revised in 2007 [163], diagnosis of HLH is still
difficult since most criteria are not specific for HLH. In reality, HLH patients may be
missed because some initial symptoms are rather nondescript [161], may be disguised as
a normal infection, or may overlap with some immune deficient disorders. It is critical to
find reliable methods to screen early HLH in order to initiate life-saving therapy.
Based on our study of FHL4 patients with mutations in the syntaxin-11 gene, the
extent of the platelet secretion defect may be determined by the loss of syntaxin-11. It
seems promising that the simple FACS analysis of the intra-platelet syntaxin-11 level
could be used as a primary screen of patients with bleeding problems to exclude the
possibility of FHL4 or severe FHL5 cases. A small amount of whole blood is required
for the FACS analysis.

Murata et al. [169] have shown that FACS analysis of

intraplatelet Munc13-4 protein is a sensitive and reliable method to screen for FHL3.
Here we propose that FACS analysis of platelets may be a good way to rapidly screen for
three isotypes of FHL: 3, 4, and 5. This technique is easy to combine with the analysis of
P-selectin exposure allowing determination of whether there is a secretion defect from αgranules upon thrombin stimulation. In addition, almost all medical centers have the
facility to perform the platelet aggregation and ATP release from dense granules using
lumi-aggregometry. Thus analysis of platelets from suspected FHL patients is a simple
and reliable way to assist in the diagnosis of FHL subtypes and other associated HLH. If
platelet function analysis is normal, at least FHL3-5 can be excluded. Analysis of CTL
functions, genetic testing, and screening for primary immunodeficiencies such as XLP
and CHS should be followed.
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Finally, western blotting analysis of protein level of Munc13-4, Munc18b,
syntaxin-11, and Rab27 in platelets can confirm the above FACS analysis for FHL
diagnosis.

Munc13-4 is a 120 kDa cytosolic protein and is expressed much more

abundantly in platelets than in peripheral blood mononuclear cells (PBMCs) [169].
Mun18b, a 67 kDa cytosolic protein, is extensively expressed in platelets. Syntaxin-11 is
a 35 kDa membrane associated protein. The maximal platelet number required for
detection of syntaxin-11 is around 5 × 105, which means around 0.5 µL normal whole
blood are needed. Since the different sizes of these proteins are enough to be separated
from SDS-PAGE, western blotting would be a good method to determine which protein
is missing. Although it takes around 6 hours, the results are accurate and reliable. The
same membrane could also be probed for Rab27a, which would further provide
information for screening other genetic causes of HLH. No more than 1 mL of whole
blood is required to for western blotting analysis.

Summary
The work presented here, for the first time, gives a picture of how syntaxin-11 and
tomosyn-1 are used to mediate platelet exocytosis. Syntaxin-11 is the primary t-SNARE
required for platelet exocytosis while syntaxin-2/4 may play a secondary role in the
absence of syntaxin-11 but not as efficiently as syntaxin-11.

Although the precise

mechanism of syntaxin-11 function in platelet exocytosis, we can clearly pinpoint that
syntaxin-11 is an important, core element of the secretory machinery.

The work

presented elucidates a complete picture of the core secretory machinery in term of which
isoforms of t- or v-SNARE are required for platelet secretion. Syntaxin-11, SNAP-23,
and VAMP-8 are the functional SNARE proteins for platelet exocytosis. In addition to
the core SNARE secretory machinery components, a novel syntaxin-binding protein in
platelets, tomosyn-1 was shown to be required for platelet secretion. Tomosyn-1 is
associated with the functional t-SNARE complex, syntaxin-11/SNAP-23 heterodimers.
Future work will focus on how granule secretion is regulated and how the core machinery
is coupled to the platelet signaling cascades that are activated by agonists. The answers
to these questions will yield a better understanding of the control mechanism of platelet
exocytosis and give directions for pharmaceutical design.
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Table 3Table 5-1. SNAREs and Their Regulators in Human and Murine Platelets

Table 5-1. SNAREs and Their Regulators in Human and Murine Platelets
t-SNAREs

Molecules/Platelet*
Human

Murine

VAMP-2†

<806

7,629 ± 89

VAMP-3†

4,588 ± 658

3,080 ± 10

VAMP-7†

3,766 ± 696

2,712 ± 230

VAMP-8†

6,590 ± 370

8,360 ± 110

SNAP-23

19,374 ± 5384

5,363 ± 798

Syntaxin-2

1,579 ± 429

1,766 ± 121

Syntaxin-4

9,633 ± 75

1,625 ± 184

Syntaxin-7

3,861 ± 564

3,707 ± 372

Syntaxin-11

51,717 ± 5459

46,966 ± 5516

Munc13-4#

ND

318 ± 47

Tomosyn-1

1029 ± 80

1152 ± 46

ND indicates not determined.
*Number of molecules per platelet was calculated using the molecular weight for VAMP2 (13 kDa), VAMP-3 (11 kDa), VAMP-7 (25 kDa), VAMP-8 (12 kDa), SNAP-23 (23
kDa), Syntaxin-2 (33 kDa), Syntaxin-4 (34 kDa), Syntaxin-7 (30 kDa), Syntaxin-11 (33
kDa), Munc13-4 (125 kDa), Tomosyn-1 (128 kDa).
#From Ren at al.[48]
†From Graham at al. [13]
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Figure 0-1Figure 5-1. A Model of Platelet Secretory Machinery

Figure 5-1. A Model of Platelet Secretory Machinery. Platelet exocytosis is mediated
by SNAREs and their regulatory proteins upon physiological stimulation. The core
SNARE machinery includes v-SNARE (VAMP) on vesicle membrane and t-SNAREs
(syntaxin-type and SNAP-25-type) on target membrane. The primary SNAREs required
for platelet secretion are VAMP-8 (in blue), syntaxin-11 (in red), and SNAP-23 (in
green) in platelets. Munc13-4 (in blue), Munc18b (in purple), tomosyn-1 (in cyan) are
required for regulation of vesicle priming, probably facilitating fusogenic SNARE
complex formation, thus leading to membrane fusion and releasing granule contents upon
stimulation.
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Abbrieviations
5-HT

serotonin (5-hydroxytryptamine)

ADP

adenosine biphosphate

ATP

adenosine triphosphate

BCA

bicinchoninic acid

β-TG

β-thromboglobulin

DAG

diacylglycerol

DMP

dimethyl pimelimidate

ECF

enhanced chemi-fluorescence

EGF

epidermal growth factor

ELISA

enzyme-linked immunosorbent assay

FACS

fluorescent-activated cell sorting

FBS

fetal bovine serum

GST

Glutathione S-transferase

FHL3

familial hemophagocytic lymphohistiocytosis type 3

FHL4

familial hemophagocytic lymphohistiocytosis type 4

FHL5

familial hemophagocytic lymphohistiocytosis type 5

FITC

fluorescein isothiocyanate

HPS

Hermansky-Pudlak syndrome

HRP

horseradish peroxidase

HUVEC

human umbilical vein endothelial cell

IP

immunoprecipitation

IP3

inositol tri-phosphate

IPTG

isopropyl-beta-D-thiogalactopyranoside

LAMP

lysosomal associated membrane protein

LDL

low density lipoprotein

lgl

legthal ginat lavea

LTP

long term potential

MBP

maltose binding protein

MHD

munc homolog domain
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MI

myocardial infarction

MVB

multivesicular body

NK

Natural Killer

NSF

N-ethylmaleimide sensitive factor

OCS

Open Canalicular System

PAGE

polyacrylamide gel electrophoresis

PAR

Protease-activated receptor

PE

platelet extract

PF4

platelet factor IV

PGI2

prostaglandin I2

PI3P

phosphatidyl inositol tri-phosphate

PKA

protein kinase A

PKC

protein kinase C

PMA

phorbol 12-myristate 13-acetate

PMSF

phenylmethanesulphonylfluoride

PRP

platelet rich plasma

PVDF

polyvinylidene fluoride

RRP

ready releasable pool

RT

room temperature

SLO

streptolysin-O

Slp

synaptotagmin like protein

SNAP-23

synaptosome-associated protein of 23 kDa

SNAP-25

synaptosome-associated protein of 25 kDa

SNARE

soluble N-ethylmaleimide-sensitive fusion protein attachment
protein receptor

SNP

single nucleotide polymorphism

SPD

Storage pool disease

TCA

tricholoracetic acid

TF

tissue factor

TGN

trans-Golgi network

TIRF

total internal reflection fluorescence
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VEGF

vascular endothelial growth factor

VAMP

vesicle associated membrane proteins

vWF

von Willebrand factor

WPB

Weibel-Palade body

Wt

wild-type
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